Bradley T Hyman

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6204625/publications.pdf

Version: 2024-02-01

598 papers	121,978 citations	154 156 h-index	154 325 g-index
642 all docs	642 docs citations	642 times ranked	81850 citing authors

#	Article	IF	Citations
1	The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Agingâ€Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's and Dementia, 2011, 7, 263-269.	0.8	12,681
2	An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. NeuroImage, 2006, 31, 968-980.	4.2	10,125
3	Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology, 1992, 42, 631-631.	1.1	2,379
4	Neuropathological Alterations in Alzheimer Disease. Cold Spring Harbor Perspectives in Medicine, 2011, 1, a006189-a006189.	6.2	2,365
5	National Institute on Agingâ€“Alzheimerâ€™s Association guidelines for the neuropathologic assessment of Alzheimerâ€™s disease: a practical approach. Acta Neuropathologica, 2012, 123, 1-11.	7.7	2,002
6	National Institute on Agingâ€“Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimer's and Dementia, 2012, 8, 1-13.	0.8	1,968
7	Genetic meta-analysis of diagnosed Alzheimerâ€™s disease identifies new risk loci and implicates AÎ², tau, immunity and lipid processing. Nature Genetics, 2019, 51, 414-430.	21.4	1,962
8	Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nature Genetics, 2011, 43, 436-441.	21.4	1,676
9	Live tissue intrinsic emission microscopy using multiphoton-excited native fluorescence and second harmonic generation. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 7075-7080.	7.1	1,630
10	Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature. Journal of Neuropathology and Experimental Neurology, 2012, 71, 362-381.	1.7	1,599
11	Profound Loss of Layer II Entorhinal Cortex Neurons Occurs in Very Mild Alzheimerâ€™s Disease. Journal of Neuroscience, 1996, 16, 4491-4500.	3.6	1,570
12	Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Annals of Neurology, 1997, 41, 17-24.	5.3	1,243
13	Propagation of Tau Pathology in a Model of Early Alzheimer's Disease. Neuron, 2012, 73, 685-697.	8.1	1,191
14	Analysis of shared heritability in common disorders of the brain. Science, 2018, 360, .	12.6	1,085
15	Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathologica, 2014, 128, 755-766.	7.7	1,060
16	Apolipoprotein E in sporadic Alzheimer's disease: Allelic variation and receptor interactions. Neuron, 1993, 11, 575-580.	8.1	1,057
17	Sirtuin 2 Inhibitors Rescue Î±-Synuclein-Mediated Toxicity in Models of Parkinson's Disease. Science, 2007, 317, 516-519.	12.6	995
18	Rapid appearance and local toxicity of amyloid-Î² plaques in a mouse model of Alzheimerâ€™s disease. Nature, 2008, 451, 720-724.	27.8	916

#	Article	IF	Citations
19	Amyloid Deposition Is Associated with Impaired Default Network Function in Older Persons without Dementia. Neuron, 2009, 63, 178-188.	8.1	899
20	Editorial on Consensus Recommendations for the Postmortem Diagnosis of Alzheimer Disease from the National Institute on Aging and the Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 1997, 56, 1095-1097.	1.7	872
21	The Alzheimer's Disease-Associated Amyloid Î²-Protein Is an Antimicrobial Peptide. PLoS ONE, 2010, 5, e9505.	2.5	868
22	The Intersection of Amyloid Beta and Tau at Synapses in Alzheimerâ€™s Disease. Neuron, 2014, 82, 756-771.	8.1	862
23	Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nature Neuroscience, 1999, 2, 271-276.	14.8	855
24	Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta Neuropathologica, 2002, 103, 26-35.	7.7	849
25	Alzheimer disease. Nature Reviews Disease Primers, 2021, 7, 33.	30.5	784
26	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nature Genetics, 2017, 49, 1373-1384.	21.4	783
27	Tau positron emission tomographic imaging in aging and early <scp>A</scp>lzheimer disease. Annals of Neurology, 2016, 79, 110-119.	5.3	778
28	Alzheimerâ€™s Disease Risk Gene CD33 Inhibits Microglial Uptake of Amyloid Beta. Neuron, 2013, 78, 631-643.	8.1	776
29	Endocytic Pathway Abnormalities Precede Amyloid Î² Deposition in Sporadic Alzheimerâ€™s Disease and Down Syndrome. American Journal of Pathology, 2000, 157, 277-286.	3.8	737
30	Oligomeric amyloid Î² associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 4012-4017.	7.1	734
31	Tau protein liquidâ€“liquid phase separation can initiate tau aggregation. EMBO Journal, 2018, 37, .	7.8	696
32	Alpha-2 macroglobulin is genetically associated with Alzheimer disease. Nature Genetics, 1998, 19, 357-360.	21.4	680
33	Î²-Secretase Protein and Activity Are Increased in the Neocortex in Alzheimer Disease. Archives of Neurology, 2002, 59, 1381.	4.5	656
34	Use of structural magnetic resonance imaging to predict who will get Alzheimer's disease. Annals of Neurology, 2000, 47, 430-439.	5.3	607
35	Synchronous Hyperactivity and Intercellular Calcium Waves in Astrocytes in Alzheimer Mice. Science, 2009, 323, 1211-1215.	12.6	606
36	APPSW Transgenic Mice Develop Age-related AÎ² Deposits and Neuropil Abnormalities, but no Neuronal Loss in CA1. Journal of Neuropathology and Experimental Neurology, 1997, 56, 965-973.	1.7	597

#	Article	IF	Citations
37	Neuronal sorting protein-related receptor sorLA/LR11 regulates processing of the amyloid precursor protein. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 13461-13466.	7.1	582
38	Synergy between amyloid-Î² and tau in Alzheimerâ€™s disease. Nature Neuroscience, 2020, 23, 1183-1193.	14.8	579
39	Alzheimerâ€“associated presenilins 1 and 2 : Neuronal expression in brain and localization to intracellular membranes in mammalian cells. Nature Medicine, 1996, 2, 224-229.	30.7	573
40	Do defecs in mitochondrial energy metabolism underlie the pathology of neurodegenerative diseases?. Trends in Neurosciences, 1993, 16, 125-131.	8.6	563
41	AÎ² Plaques Lead to Aberrant Regulation of Calcium Homeostasis In Vivo Resulting in Structural and Functional Disruption of Neuronal Networks. Neuron, 2008, 59, 214-225.	8.1	551
42	Validating novel tau positron emission tomography tracer <scp>[Fâ€18]â€AVâ€1451 (T807)</scp> on postmortem brain tissue. Annals of Neurology, 2015, 78, 787-800.	5.3	535
43	Attenuation of Delayed Neuronal Death after Mild Focal Ischemia in Mice by Inhibition of the Caspase Family. Journal of Cerebral Blood Flow and Metabolism, 1998, 18, 238-247.	4.3	532
44	Utility of the Apolipoprotein E Genotype in the Diagnosis of Alzheimer's Disease. New England Journal of Medicine, 1998, 338, 506-511.	27.0	530
45	The Major Risk Factors for Alzheimerâ€™s Disease: Age, Sex, and Genes Modulate the Microglia Response to AÎ² Plaques. Cell Reports, 2019, 27, 1293-1306.e6.	6.4	527
46	Dendritic Spine Abnormalities in Amyloid Precursor Protein Transgenic Mice Demonstrated by Gene Transfer and Intravital Multiphoton Microscopy. Journal of Neuroscience, 2005, 25, 7278-7287.	3.6	524
47	LDL receptor-related protein, a multifunctional ApoE receptor, binds secreted Î²-amyloid precursor protein and mediates its degradation. Cell, 1995, 82, 331-340.	28.9	499
48	AÎ² Deposition Is Associated with Neuropil Changes, but not with Overt Neuronal Loss in the Human Amyloid Precursor Protein V717F (PDAPP) Transgenic Mouse. Journal of Neuroscience, 1997, 17, 7053-7059.	3.6	490
49	Apolipoprotein E Ïµ4 and cerebral hemorrhage associated with amyloid angiopathy. Annals of Neurology, 1995, 38, 254-259.	5.3	488
50	Caspase activation precedes and leads to tangles. Nature, 2010, 464, 1201-1204.	27.8	463
51	Imaging of amyloid-Î² deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nature Medicine, 2001, 7, 369-372.	30.7	462
52	Hsp70 Reduces Î±-Synuclein Aggregation and Toxicity. Journal of Biological Chemistry, 2004, 279, 25497-25502.	3.4	460
53	Amyotrophic Lateral Sclerosis-Associated SOD1 Mutant Proteins Bind and Aggregate with Bcl-2 in Spinal Cord Mitochondria. Neuron, 2004, 43, 19-30.	8.1	452
54	Acyl-coenzyme A: cholesterol acyltransferase modulates the generation of the amyloid Î²-peptide. Nature Cell Biology, 2001, 3, 905-912.	10.3	444

#	Article	IF	Citations
55	At the interface of sensory and motor dysfunctions and Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 70-98.	0.8	420
56	Entorhinal cortex pathology in Alzheimer's disease. Hippocampus, 1991, 1, 1-8.	1.9	418
57	Reversible Memory Loss in a Mouse Transgenic Model of Alzheimer's Disease. Journal of Neuroscience, 2002, 22, 6331-6335.	3.6	417
58	H. M.â€™s Medial Temporal Lobe Lesion: Findings from Magnetic Resonance Imaging. Journal of Neuroscience, 1997, 17, 3964-3979.	3.6	407
59	Abnormal bundling and accumulation of F-actin mediates tau-induced neuronal degeneration in vivo. Nature Cell Biology, 2007, 9, 139-148.	10.3	399
60	APOE and Alzheimer's disease: advances in genetics, pathophysiology, and therapeutic approaches. Lancet Neurology, The, 2021, 20, 68-80.	10.2	399
61	Clinical and pathological correlates of apolipoprotein E Îµ4 in Alzheimer's disease. Annals of Neurology, 1996, 39, 62-70.	5.3	380
62	Reactive Glia not only Associates with Plaques but also Parallels Tangles in Alzheimer's Disease. American Journal of Pathology, 2011, 179, 1373-1384.	3.8	379
63	Isolation and characterization of APLP2 encoding a homologue of the Alzheimer's associated amyloid Î² protein precursor. Nature Genetics, 1993, 5, 95-100.	21.4	370
64	The Synaptic Accumulation of Hyperphosphorylated Tau Oligomers in Alzheimer Disease Is Associated With Dysfunction of the Ubiquitin-Proteasome System. American Journal of Pathology, 2012, 181, 1426-1435.	3.8	369
65	Imaging AÎ² Plaques in Living Transgenic Mice with Multiphoton Microscopy and Methoxy-X04, a Systemically Administered Congo Red Derivative. Journal of Neuropathology and Experimental Neurology, 2002, 61, 797-805.	1.7	366
66	Ageâ€Dependent Vulnerability of the Striatum to the Mitochondrial Toxin 3â€Nitropropionic Acid. Journal of Neurochemistry, 1993, 60, 356-359.	3.9	365
67	Nigral and Cortical Lewy Bodies and Dystrophic Nigral Neurites in ParkinsonÊ¼s Disease and Cortical Lewy Body Disease Contain Î±-synuclein Immunoreactivity. Journal of Neuropathology and Experimental Neurology, 1998, 57, 334-337.	1.7	355
68	Tau PTM Profiles Identify Patient Heterogeneity and Stages of Alzheimerâ€™s Disease. Cell, 2020, 183, 1699-1713.e13.	28.9	354
69	Formation of Toxic Oligomeric Î±-Synuclein Species in Living Cells. PLoS ONE, 2008, 3, e1867.	2.5	354
70	Region-specific Dissociation of Neuronal Loss and Neurofibrillary Pathology in a Mouse Model of Tauopathy. American Journal of Pathology, 2006, 168, 1598-1607.	3.8	349
71	A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain. Bioorganic and Medicinal Chemistry Letters, 2002, 12, 295-298.	2.2	343
72	Dysferlin Interacts with Annexins A1 and A2 and Mediates Sarcolemmal Wound-healing. Journal of Biological Chemistry, 2003, 278, 50466-50473.	3.4	336

#	Article	IF	Citations
73	Human LilrB2 Is a Î²-Amyloid Receptor and Its Murine Homolog PirB Regulates Synaptic Plasticity in an Alzheimerâ€™s Model. Science, 2013, 341, 1399-1404.	12.6	335
74	Amyloid Î² Induces the Morphological Neurodegenerative Triad of Spine Loss, Dendritic Simplification, and Neuritic Dystrophies through Calcineurin Activation. Journal of Neuroscience, 2010, 30, 2636-2649.	3.6	328
75	Molecular Imaging With Pittsburgh Compound B Confirmed at Autopsy. Archives of Neurology, 2007, 64, 431.	4.5	326
76	LRP1 is a master regulator of tau uptake and spread. Nature, 2020, 580, 381-385.	27.8	326
77	TorsinA and heat shock proteins act as molecular chaperones: suppression of Î±â€synuclein aggregation. Journal of Neurochemistry, 2002, 83, 846-854.	3.9	318
78	Non-Fc-Mediated Mechanisms Are Involved in Clearance of Amyloid-Î²In Vivoby Immunotherapy. Journal of Neuroscience, 2002, 22, 7873-7878.	3.6	314
79	Distinct RolesIn Vivofor the Ubiquitinâ€“Proteasome System and the Autophagyâ€“Lysosomal Pathway in the Degradation of Î±-Synuclein. Journal of Neuroscience, 2011, 31, 14508-14520.	3.6	311
80	Genetic assessment of age-associated Alzheimer disease risk: Development and validation of a polygenic hazard score. PLoS Medicine, 2017, 14, e1002258.	8.4	311
81	Genome-Wide Association Meta-analysis of Neuropathologic Features of Alzheimer's Disease and Related Dementias. PLoS Genetics, 2014, 10, e1004606.	3.5	305
82	Multiple, diverse senile plaque-associated proteins are ligands of an apolipoprotein e receptor, the ?2-macroglobulin receptor/low-density-lipoprotein receptor?related protein. Annals of Neurology, 1995, 37, 211-217.	5.3	304
83	In Vivo Optical Imaging of Amyloid Aggregates in Brain: Design of Fluorescent Markers. Angewandte Chemie - International Edition, 2005, 44, 5452-5456.	13.8	303
84	Tau Protein Disrupts Nucleocytoplasmic Transport in Alzheimerâ€™s Disease. Neuron, 2018, 99, 925-940.e7.	8.1	302
85	Parkin Localizes to the Lewy Bodies of Parkinson Disease and Dementia with Lewy Bodies. American Journal of Pathology, 2002, 160, 1655-1667.	3.8	299
86	The Co-chaperone Carboxyl Terminus of Hsp70-interacting Protein (CHIP) Mediates Î±-Synuclein Degradation Decisions between Proteasomal and Lysosomal Pathways. Journal of Biological Chemistry, 2005, 280, 23727-23734.	3.4	298
87	Dissecting phenotypic traits linked to human resilience to Alzheimerâ€™s pathology. Brain, 2013, 136, 2510-2526.	7.6	294
88	Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer's disease model. Annals of Neurology, 2000, 47, 739-747.	5.3	293
89	Age-Dependent Striatal Excitotoxic Lesions Produced by the Endogenous Mitochondrial Inhibitor Malonate. Journal of Neurochemistry, 1993, 61, 1147-1150.	3.9	289
90	Amyloid Î²-Peptide Is Transported on Lipoproteins and Albumin in Human Plasma. Journal of Biological Chemistry, 1996, 271, 32916-32922.	3.4	286

#	Article	IF	Citations
91	Caspase activation and neuroprotection in caspase-3- deficient mice after in vivo cerebral ischemia and in vitro oxygen glucose deprivation. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 15188-15193.	7.1	285
92	Tau pathophysiology in neurodegeneration: a tangled issue. Trends in Neurosciences, 2009, 32, 150-159.	8.6	284
93	Neuronal uptake and propagation of a rare phosphorylated high-molecular-weight tau derived from Alzheimerâ€™s disease brain. Nature Communications, 2015, 6, 8490.	12.8	283
94	Neuronal expression of myeloperoxidase is increased in Alzheimer's disease. Journal of Neurochemistry, 2004, 90, 724-733.	3.9	278
95	Local Nucleation of Microtubule Bundles through Tubulin Concentration into a Condensed Tau Phase. Cell Reports, 2017, 20, 2304-2312.	6.4	278
96	Tau impairs neural circuits, dominating amyloid-Î² effects, in Alzheimer models in vivo. Nature Neuroscience, 2019, 22, 57-64.	14.8	278
97	Heatâ€shock protein 70 modulates toxic extracellular Î±â€synuclein oligomers and rescues transâ€synaptic toxicity. FASEB Journal, 2011, 25, 326-336.	0.5	276
98	Immunohistochemical Study of the Î²-Chemokine Receptors CCR3 and CCR5 and Their Ligands in Normal and Alzheimer's Disease Brains. American Journal of Pathology, 1998, 153, 31-37.	3.8	274
99	Apolipoprotein E4 effects in Alzheimerâ€™s disease are mediated by synaptotoxic oligomeric amyloid-Î². Brain, 2012, 135, 2155-2168.	7.6	268
100	Î²-Secretase Activity Increases with Aging in Human, Monkey, and Mouse Brain. American Journal of Pathology, 2004, 164, 719-725.	3.8	267
101	Metaâ€analysis of Parkinson's Disease: Identification of a novel locus, RIT2. Annals of Neurology, 2012, 71, 370-384.	5.3	264
102	Tau molecular diversity contributes to clinical heterogeneity in Alzheimerâ€™s disease. Nature Medicine, 2020, 26, 1256-1263.	30.7	262
103	A novel Alzheimer disease locus located near the gene encoding tau protein. Molecular Psychiatry, 2016, 21, 108-117.	7.9	260
104	Chemokines/chemokine receptors in the central nervous system and Alzheimer's disease. Journal of NeuroVirology, 1999, 5, 32-41.	2.1	258
105	Uniform polarity microtubule assemblies imaged in native brain tissue by second-harmonic generation microscopy. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 7081-7086.	7.1	253
106	Four-dimensional multiphoton imaging of brain entry, amyloid binding, and clearance of an amyloid-Â ligand in transgenic mice. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 12462-12467.	7.1	253
107	Age but Not Diagnosis Is the Main Predictor of Plasma Amyloid Î²-Protein Levels. Archives of Neurology, 2003, 60, 958.	4.5	250
108	Demonstration by FRET of BACE interaction with the amyloid precursor protein at the cell surface and in early endosomes. Journal of Cell Science, 2003, 116, 3339-3346.	2.0	247

#	Article	IF	Citations
109	Exceptionally low likelihood of Alzheimerâ€™s dementia in APOE2 homozygotes from a 5,000-person neuropathological study. Nature Communications, 2020, 11, 667.	12.8	246
110	Pharmacological promotion of inclusion formation: A therapeutic approach for Huntingtonâ€™s and Parkinsonâ€™s diseases. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 4246-4251.	7.1	244
111	Expression of the chemokine receptor CXCR3 on neurons and the elevated expression of its ligand IP-10 in reactive astrocytes: in vitro ERK1/2 activation and role in Alzheimerâ€™s disease. Journal of Neuroimmunology, 2000, 108, 227-235.	2.3	243
112	The Lack of Accumulation of Senile Plaques or Amyloid Burden in AlzheimerÊ¼s Disease Suggests a Dynamic Balance Between Amyloid Deposition and Resolution. Journal of Neuropathology and Experimental Neurology, 1993, 52, 594-600.	1.7	241
113	Application of the National Institute on Aging (NIA)-Reagan Institute Criteria for the Neuropathological Diagnosis of Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 1999, 58, 1147-1155.	1.7	240
114	Beyond the neuronâ€“cellular interactions early in Alzheimer disease pathogenesis. Nature Reviews Neuroscience, 2019, 20, 94-108.	10.2	237
115	Association of In Vivo [¹⁸F]AV-1451 Tau PET Imaging Results With Cortical Atrophy and Symptoms in Typical and Atypical Alzheimer Disease. JAMA Neurology, 2017, 74, 427.	9.0	236
116	Modulation of Î²-Amyloid Precursor Protein Processing by the Low Density Lipoprotein Receptor-related Protein (LRP). Journal of Biological Chemistry, 2000, 275, 7410-7415.	3.4	233
117	Î³-Secretase Heterogeneity in the Aph1 Subunit: Relevance for Alzheimerâ€™s Disease. Science, 2009, 324, 639-642.	12.6	233
118	Family-Based Association between Alzheimer's Disease and Variants inUBQLN1. New England Journal of Medicine, 2005, 352, 884-894.	27.0	232
119	The Low Density Lipoprotein Receptor-related Protein (LRP) Is a Novel Î²-Secretase (BACE1) Substrate. Journal of Biological Chemistry, 2005, 280, 17777-17785.	3.4	228
120	Nanoparticles enhance brain delivery of bloodâ€“brain barrier-impermeable probes for in vivo optical and magnetic resonance imaging. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 18837-18842.	7.1	228
121	Tau Accumulation Causes Mitochondrial Distribution Deficits in Neurons in a Mouse Model of Tauopathy and in Human Alzheimer's Disease Brain. American Journal of Pathology, 2011, 179, 2071-2082.	3.8	224
122	Tau induces blood vessel abnormalities and angiogenesis-related gene expression in P301L transgenic mice and human Alzheimerâ€™s disease. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E1289-E1298.	7.1	224
123	Age-Related Amyloid Î² Deposition in Transgenic Mice Overexpressing Both Alzheimer Mutant Presenilin 1 and Amyloid Î² Precursor Protein Swedish Mutant Is Not Associated with Global Neuronal Loss. American Journal of Pathology, 2000, 157, 331-339.	3.8	222
124	Membrane Association and Protein Conformation of Î±-Synuclein in Intact Neurons. Journal of Biological Chemistry, 2000, 275, 8812-8816.	3.4	219
125	Apolipoprotein E, Especially Apolipoprotein E4, Increases the Oligomerization of Amyloid Î² Peptide. Journal of Neuroscience, 2012, 32, 15181-15192.	3.6	219
126	Apoptotic and non-apoptotic roles of caspases in neuronal physiology and pathophysiology. Nature Reviews Neuroscience, 2012, 13, 395-406.	10.2	218

#	Article	IF	Citations
127	Alzheimer's disease: Glutamate depletion in the hippocampal perforant pathway zone. Annals of Neurology, 1987, 22, 37-40.	5.3	212
128	Apolipoprotein E Îµ4 Is Associated With the Presence and Earlier Onset of Hemorrhage in Cerebral Amyloid Angiopathy. Stroke, 1996, 27, 1333-1337.	2.0	212
129	Nonsteroidal anti-inflammatory drugs lower AÎ²42 and change presenilin 1 conformation. Nature Medicine, 2004, 10, 1065-1066.	30.7	206
130	Synaptic Tau Seeding Precedes Tau Pathology in Human Alzheimer's Disease Brain. Frontiers in Neuroscience, 2018, 12, 267.	2.8	198
131	Cortical Synaptic Integration In Vivo Is Disrupted by Amyloid-Â Plaques. Journal of Neuroscience, 2004, 24, 4535-4540.	3.6	196
132	Mechanisms of Protein Seeding in Neurodegenerative Diseases. JAMA Neurology, 2013, 70, 304.	9.0	195
133	Î±-Synuclein strains target distinct brain regions and cell types. Nature Neuroscience, 2020, 23, 21-31.	14.8	195
134	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyride Neurotoxicity Is Attenuated in Mice Overexpressing Bcl-2. Journal of Neuroscience, 1998, 18, 8145-8152.	3.6	193
135	Dopamine D₁Activation Potentiates Striatal NMDA Receptors by Tyrosine Phosphorylation-Dependent Subunit Trafficking. Journal of Neuroscience, 2006, 26, 4690-4700.	3.6	193
136	Mechanisms of Reduced Striatal NMDA Excitotoxicity in Type I Nitric Oxide Synthase Knock-Out Mice. Journal of Neuroscience, 1997, 17, 6908-6917.	3.6	187
137	Characterization of the Precursor Protein of the Non-AÎ² Component of Senile Plaques (NACP) in the Human Central Nervous System. Journal of Neuropathology and Experimental Neurology, 1996, 55, 889-895.	1.7	185
138	Soluble forms of tau are toxic in Alzheimerâ€™s disease. Translational Neuroscience, 2012, 3, 223-233.	1.4	185
139	Development of the Superior Temporal Neocortex Is Anomalous in Trisomy 21. Journal of Neuropathology and Experimental Neurology, 1994, 53, 513-520.	1.7	182
140	Interaction of Reelin with Amyloid Precursor Protein Promotes Neurite Outgrowth. Journal of Neuroscience, 2009, 29, 7459-7473.	3.6	182
141	Transgenic models of Alzheimerâ€™s disease: Learning from animals. NeuroRx, 2005, 2, 423-437.	6.0	180
142	Small heat shock proteins protect against Î±-synuclein-induced toxicity and aggregation. Biochemical and Biophysical Research Communications, 2006, 351, 631-638.	2.1	180
143	The role of microglia in processing and spreading of bioactive tau seeds in Alzheimerâ€™s disease. Journal of Neuroinflammation, 2018, 15, 269.	7.2	180
144	Impaired Spine Stability Underlies Plaque-Related Spine Loss in an Alzheimer's Disease Mouse Model. American Journal of Pathology, 2007, 171, 1304-1311.	3.8	179

#	Article	IF	Citations
145	Novel allele-dependent role for APOE in controlling the rate of synapse pruning by astrocytes. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 10186-10191.	7.1	179
146	Geldanamycin induces Hsp70 and prevents Î±-synuclein aggregation and toxicity in vitro. Biochemical and Biophysical Research Communications, 2004, 321, 665-669.	2.1	178
147	Relative sparing of nitric oxide synthase-containing neurons in the hippocampal formation in Alzheimer's disease. Annals of Neurology, 1992, 32, 818-820.	5.3	177
148	Motor dysfunction and gliosis with preserved dopaminergic markers in human Î±-synuclein A30P transgenic mice. Neurobiology of Aging, 2003, 24, 245-258.	3.1	177
149	Amyloid accelerates tau propagation and toxicity in a model of early Alzheimerâ€™s disease. Acta Neuropathologica Communications, 2015, 3, 14.	5.2	176
150	Pathological correlations of [Fâ€18]â€AVâ€1451 imaging in nonâ€alzheimer tauopathies. Annals of Neurology, 2017, 81, 117-128.	5.3	174
151	Amyloid-Dependent and Amyloid-Independent Stages of Alzheimer Disease. Archives of Neurology, 2011, 68, 1062.	4.5	173
152	Chapter 32 Hippocampal formation: anatomy and the patterns of pathology in Alzheimer's disease. Progress in Brain Research, 1990, 83, 445-457.	1.4	171
153	Poor Performance on a Preoperative Cognitive Screening Test Predicts Postoperative Complications in Older Orthopedic Surgical Patients. Anesthesiology, 2017, 127, 765-774.	2.5	171
154	Neurofibrillary tangle-bearing neurons are functionally integrated in cortical circuits in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 510-514.	7.1	170
155	Subjective Cognitive Concerns and Neuropsychiatric Predictors of ProgressionÂto the Early Clinical Stages ofÂAlzheimer Disease. American Journal of Geriatric Psychiatry, 2014, 22, 1642-1651.	1.2	167
156	Enhanced Tau Aggregation in the Presence of Amyloid Î². American Journal of Pathology, 2017, 187, 1601-1612.	3.8	167
157	Effects of Multiple Genetic Loci on Age at Onset in Late-Onset Alzheimer Disease. JAMA Neurology, 2014, 71, 1394.	9.0	166
158	Progression of Cerebral Amyloid Angiopathy: Accumulation of Amyloid-ÃŸ40 in Affected Vessels. Journal of Neuropathology and Experimental Neurology, 1998, 57, 353-359.	1.7	164
159	Age-dependent cerebrovascular dysfunction in a transgenic mouse model of cerebral amyloid angiopathy. Brain, 2007, 130, 2310-2319.	7.6	164
160	Dopaminergic neuron loss and up-regulation of chaperone protein mRNA induced by targeted over-expression of alpha-synuclein in mouse substantia nigra. Journal of Neurochemistry, 2007, 100, 070214184024010-???.	3.9	164
161	Preservation of Neuronal Number Despite Age-Related Cortical Brain Atrophy in Elderly Subjects Without Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 2008, 67, 1205-1212.	1.7	164
162	Crystal structure of the complete integrin Î±VÎ²3 ectodomain plus an Î±/Î² transmembrane fragment. Journal of Cell Biology, 2009, 186, 589-600.	5.2	163

#	Article	IF	Citations
163	Differential Relationships of Reactive Astrocytes and Microglia to Fibrillar Amyloid Deposits in Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 2013, 72, 462-471.	1.7	163
164	1-Methyl-4-Phenylpyridinium Produces Excitotoxic Lesions in Rat Striatum as a Result of Impairment of Oxidative Metabolism. Journal of Neurochemistry, 1992, 58, 1975-1978.	3.9	162
165	Interaction of the Cytosolic Domains of sorLA/LR11 with the Amyloid Precursor Protein (APP) and Î²-Secretase Î²-Site APP-Cleaving Enzyme. Journal of Neuroscience, 2006, 26, 418-428.	3.6	162
166	Brain-Permeable Small-Molecule Inhibitors of Hsp90 Prevent Î±-Synuclein Oligomer Formation and Rescue Î±-Synuclein-Induced Toxicity. Journal of Pharmacology and Experimental Therapeutics, 2010, 332, 849-857.	2.5	162
167	Endocytic receptor LRP together with tPA and PAI-1 coordinates Mac-1-dependent macrophage migration. EMBO Journal, 2006, 25, 1860-1870.	7.8	161
168	Anti-AÎ² antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice. Journal of Clinical Investigation, 2005, 115, 428-433.	8.2	161
169	Expression of APP pathway mRNAs and proteins in Alzheimerâ€™s disease. Brain Research, 2007, 1161, 116-123.	2.2	159
170	Tyrosine and serine phosphorylation of Î±-synuclein have opposing effects on neurotoxicity and soluble oligomer formation. Journal of Clinical Investigation, 2009, 119, 3257-65.	8.2	158
171	Warfarin-related purple toes syndrome and cholesterol microembolization. American Journal of Medicine, 1987, 82, 1233-1237.	1.5	156
172	CHIP Targets Toxic Î±-Synuclein Oligomers for Degradation. Journal of Biological Chemistry, 2008, 283, 17962-17968.	3.4	155
173	Brain Expression of Apolipoproteins E, J, and Aâ€ in Alzheimer's Disease. Journal of Neurochemistry, 1996, 66, 2429-2435.	3.9	154
174	The apoE isoform binding properties of the VLDL receptor reveal marked differences from LRP and the LDL receptor. Journal of Lipid Research, 2005, 46, 1721-1731.	4.2	154
175	Amyloid-Î² Antibody Treatment Leads to Rapid Normalization of Plaque-Induced Neuritic Alterations. Journal of Neuroscience, 2003, 23, 10879-10883.	3.6	152
176	Association Between Genetic Traits for Immune-Mediated Diseases and Alzheimer Disease. JAMA Neurology, 2016, 73, 691.	9.0	151
177	Fluorescence resonance energy transfer determinations using multiphoton fluorescence lifetime imaging microscopy to characterize amyloid-beta plaques. Journal of Biomedical Optics, 2003, 8, 368.	2.6	150
178	In VivoImaging of Reactive Oxygen Species Specifically Associated with Thioflavine S-Positive Amyloid Plaques by Multiphoton Microscopy. Journal of Neuroscience, 2003, 23, 2212-2217.	3.6	150
179	BACE Is Degraded via the Lysosomal Pathway. Journal of Biological Chemistry, 2005, 280, 32499-32504.	3.4	149
180	Role of the Î²-Chemokine Receptors CCR3 and CCR5 in Human Immunodeficiency Virus Type 1 Infection of Monocytes and Microglia. Journal of Virology, 1998, 72, 3351-3361.	3.4	146

#	Article	IF	Citations
181	Polygenic Overlap Between C-Reactive Protein, Plasma Lipids, and Alzheimer Disease. Circulation, 2015, 131, 2061-2069.	1.6	145
182	Novel Alzheimer Disease Risk Loci and Pathways in African American Individuals Using the African Genome Resources Panel. JAMA Neurology, 2021, 78, 102.	9.0	144
183	Neuropathological Changes in Down's Syndrome Hippocampal Formation. Archives of Neurology, 1995, 52, 373.	4.5	139
184	Familial Alzheimer's Disease Presenilin 1 Mutations Cause Alterations in the Conformation of Presenilin and Interactions with Amyloid Precursor Protein. Journal of Neuroscience, 2005, 25, 3009-3017.	3.6	139
185	PART, a distinct tauopathy, different from classical sporadic Alzheimer disease. Acta Neuropathologica, 2015, 129, 757-762.	7.7	139
186	Î³â€Secretase/presenilin inhibitors for Alzheimer's disease phenocopy Notch mutations inDrosophila. FASEB Journal, 2003, 17, 79-81.	0.5	138
187	Beneficial effect of human anti-amyloid-Î² active immunization on neurite morphology and tau pathology. Brain, 2010, 133, 1312-1327.	7.6	138
188	Rapid Microglial Response Around Amyloid Pathology after Systemic Anti-Aî² Antibody Administration in PDAPP Mice. Journal of Neuroscience, 2008, 28, 14156-14164.	3.6	136
189	Gene Transfer of Human Apoe Isoforms Results in Differential Modulation of Amyloid Deposition and Neurotoxicity in Mouse Brain. Science Translational Medicine, 2013, 5, 212ra161.	12.4	135
190	Autoantibodies to amyloid-? and Alzheimer's disease. Annals of Neurology, 2001, 49, 808-810.	5.3	132
191	In VivoImaging Reveals Dissociation between Caspase Activation and Acute Neuronal Death in Tangle-Bearing Neurons. Journal of Neuroscience, 2008, 28, 862-867.	3.6	132
192	<scp>APOE</scp>Îµ2 is associated with milder clinical and pathological <scp>A</scp>lzheimer disease. Annals of Neurology, 2015, 77, 917-929.	5.3	132
193	Demonstration by Fluorescence Resonance Energy Transfer of Two Sites of Interaction between the Low-Density Lipoprotein Receptor-Related Protein and the Amyloid Precursor Protein: Role of the Intracellular Adapter Protein Fe65. Journal of Neuroscience, 2001, 21, 8354-8361.	3.6	131
194	A Phenotypic Change But Not Proliferation Underlies Glial Responses in Alzheimer Disease. American Journal of Pathology, 2013, 182, 2332-2344.	3.8	131
195	Prediction of cognition in Parkinson's disease with a clinicalâ€“genetic score: a longitudinal analysis of nine cohorts. Lancet Neurology, The, 2017, 16, 620-629.	10.2	131
196	Structural and Functional Disruption of Vascular Smooth Muscle Cells in a Transgenic Mouse Model of Amyloid Angiopathy. American Journal of Pathology, 2001, 158, 1065-1071.	3.8	130
197	Fas Receptor and Neuronal Cell Death after Spinal Cord Ischemia. Journal of Neuroscience, 2000, 20, 6879-6887.	3.6	125
198	Machine learning identifies candidates for drug repurposing in Alzheimerâ€™s disease. Nature Communications, 2021, 12, 1033.	12.8	124

#	Article	IF	Citations
199	Differential effect of threeâ€repeat and fourâ€repeat tau on mitochondrial axonal transport. Journal of Neurochemistry, 2009, 111, 417-427.	3.9	123
200	Î±2-Macroglobulin Enhances the Clearance of Endogenous Soluble Î²-Amyloid Peptide via Low-Density Lipoprotein Receptor-Related Protein in Cortical Neuron. Journal of Neurochemistry, 2002, 73, 1393-1398.	3.9	122
201	Designed Helical Peptides Inhibit an Intramembrane Protease. Journal of the American Chemical Society, 2003, 125, 11794-11795.	13.7	122
202	The Î³ Secretase-generated Carboxyl-terminal Domain of the Amyloid Precursor Protein Induces Apoptosis via Tip60 in H4 Cells. Journal of Biological Chemistry, 2002, 277, 28530-28536.	3.4	121
203	Soluble oligomeric amyloid-Î² induces calcium dyshomeostasis that precedes synapse loss in the living mouse brain. Molecular Neurodegeneration, 2017, 12, 27.	10.8	120
204	Frequency of the apolipoprotein E Îµ2 allele is diminished in sporadic Alzheimer disease. Neuroscience Letters, 1994, 175, 46-48.	2.1	119
205	Rapid Progression from Mild Cognitive Impairment to Alzheimerâ€™s Disease in Subjects with Elevated Levels of Tau in Cerebrospinal Fluid and the <i>APOE </i>Îµ<i>4</i>/Îµ<i>4</i> Genotype. Dementia and Geriatric Cognitive Disorders, 2009, 27, 458-464.	1.5	119
206	Ubiquitinylation of Î±-Synuclein by Carboxyl Terminus Hsp70-Interacting Protein (CHIP) Is Regulated by Bcl-2-Associated Athanogene 5 (BAG5). PLoS ONE, 2011, 6, e14695.	2.5	119
207	Î±-Synuclein Immunoreactivity Is Present in Axonal Swellings in Neuroaxonal Dystrophy and Acute Traumatic Brain Injury. Journal of Neuropathology and Experimental Neurology, 1999, 58, 1263-1268.	1.7	118
208	Oxidative stress and lipid peroxidation are upstream of amyloid pathology. Neurobiology of Disease, 2015, 84, 109-119.	4.4	118
209	Cerebrospinal fluid levels of amyloid Î²â€protein in alzheimer's disease: Inverse correlation with severity of dementia and effect of apolipoprotein e genotype. Annals of Neurology, 1995, 37, 512-518.	5.3	117
210	CRISPR/Cas9 Mediated Disruption of the Swedish APP Allele as a Therapeutic Approach for Early-Onset Alzheimerâ€™s Disease. Molecular Therapy - Nucleic Acids, 2018, 11, 429-440.	5.1	116
211	High prevalence of <scp>NMDA</scp> receptor IgA/IgM antibodies in different dementia types. Annals of Clinical and Translational Neurology, 2014, 1, 822-832.	3.7	114
212	Aminooxyacetic Acid Results in Excitotoxin Lesions by a Novel Indirect Mechanism. Journal of Neurochemistry, 1991, 57, 1068-1073.	3.9	113
213	The normal equilibrium between CSF and plasma amyloid beta levels is disrupted in Alzheimer's disease. Neuroscience Letters, 2007, 427, 127-131.	2.1	112
214	Removing endogenous tau does not prevent tau propagation yet reduces its neurotoxicity. EMBO Journal, 2015, 34, 3028-3041.	7.8	112
215	Î±-Synuclein S129 Phosphorylation Mutants Do Not Alter Nigrostriatal Toxicity in a Rat Model of Parkinson Disease. Journal of Neuropathology and Experimental Neurology, 2009, 68, 515-524.	1.7	111
216	Brain Oligomeric Î²-Amyloid but Not Total Amyloid Plaque Burden Correlates With Neuronal Loss and Astrocyte Inflammatory Response in Amyloid Precursor Protein/Tau Transgenic Mice. Journal of Neuropathology and Experimental Neurology, 2011, 70, 360-376.	1.7	111

#	Article	IF	Citations
217	Alpha-synuclein aggregation involves a bafilomycin A₁-sensitive autophagy pathway. Autophagy, 2012, 8, 754-766.	9.1	111
218	A Close Association of TorsinA and Î±-Synuclein in Lewy Bodies. American Journal of Pathology, 2001, 159, 339-344.	3.8	110
219	Imaging Amyloid-Î² Deposits In Vivo. Journal of Cerebral Blood Flow and Metabolism, 2002, 22, 1035-1041.	4.3	110
220	Amyloid Precursor Protein Associates with a Nicastrin-Dependent Docking Site on the Presenilin 1â€“Î³-Secretase Complex in Cells Demonstrated by Fluorescence Lifetime Imaging. Journal of Neuroscience, 2003, 23, 4560-4566.	3.6	109
221	Amyloidâ€Î² associated volume loss occurs only in the presence of phosphoâ€tau. Annals of Neurology, 2011, 70, 657-661.	5.3	109
222	Alzheimerâ€™s disease cerebrospinal fluid biomarker in cognitively normal subjects. Brain, 2015, 138, 2701-2715.	7.6	109
223	Orchestrated experience-driven Arc responses are disrupted in a mouse model of Alzheimer's disease. Nature Neuroscience, 2012, 15, 1422-1429.	14.8	108
224	Retinal blood flow in mild cognitive impairment and Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2015, 1, 144-151.	2.4	108
225	Functional Alterations in Alzheimer's Disease: Selective Loss of Mitochondrial-encoded Cytochrome Oxidase mRNA in the Hippocampal Formation. Journal of Neuropathology and Experimental Neurology, 1994, 53, 508-512.	1.7	106
226	Role of the Low-density Lipoprotein Receptorâ€“Related Protein in Î²-Amyloid Metabolism and Alzheimer Disease. Archives of Neurology, 2000, 57, 646.	4.5	105
227	Targeting of nonlipidated, aggregated apoE with antibodies inhibits amyloid accumulation. Journal of Clinical Investigation, 2018, 128, 2144-2155.	8.2	105
228	Demonstration of BACE (Î²-secretase) phosphorylation and its interaction with GGA1 in cells by fluorescence-lifetime imaging microscopy. Journal of Cell Science, 2004, 117, 5437-5445.	2.0	103
229	Experimental evidence for the age dependence of tau protein spread in the brain. Science Advances, 2019, 5, eaaw6404.	10.3	103
230	Anti-ApoE Antibody Given after Plaque Onset Decreases AÎ² Accumulation and Improves Brain Function in a Mouse Model of AÎ² Amyloidosis. Journal of Neuroscience, 2014, 34, 7281-7292.	3.6	102
231	Aspartate Mutations in Presenilin and Î³-Secretase Inhibitors Both Impair Notch1 Proteolysis and Nuclear Translocation with Relative Preservation of Notch1 Signaling. Journal of Neurochemistry, 2002, 75, 583-593.	3.9	101
232	The Effects of Amyloid Precursor Protein on Postsynaptic Composition and Activity. Journal of Biological Chemistry, 2009, 284, 8495-8506.	3.4	101
233	Acetylated tau inhibits chaperone-mediated autophagy and promotes tau pathology propagation in mice. Nature Communications, 2021, 12, 2238.	12.8	101
234	Quantitation of apoE Domains in Alzheimer Disease Brain Suggests a Role for apoE in AÃŸ Aggregation. Journal of Neuropathology and Experimental Neurology, 2001, 60, 342-349.	1.7	100

#	Article	IF	Citations
235	Plasma Î² Amyloid and the Risk of Alzheimer Disease and Dementia in Elderly Men. Archives of Neurology, 2008, 65, 256-63.	4.5	100
236	Dissecting the genetic relationship between cardiovascular risk factors and Alzheimerâ€™s disease. Acta Neuropathologica, 2019, 137, 209-226.	7.7	100
237	Blockade of 1-methyl-4-phenylpyridinium ion (MPP+) nigral toxicity in the rat by prior decortication or MK-801 treatment: A stereological estimate of neuronal loss. Neurobiology of Aging, 1993, 14, 295-301.	3.1	98
238	The Intracellular Domain of the Low Density Lipoprotein Receptor-related Protein Modulates Transactivation Mediated by Amyloid Precursor Protein and Fe65. Journal of Biological Chemistry, 2003, 278, 41182-41188.	3.4	98
239	Synaptic alterations in the rTg4510 mouse model of tauopathy. Journal of Comparative Neurology, 2013, 521, 1334-1353.	1.6	98
240	Expression of the Very Low-Density Lipoprotein Receptor (VLDL-r), an Apolipoprotein-E Receptor, in the Central Nervous System and in AlzheimerÊ¼s Disease. Journal of Neuropathology and Experimental Neurology, 1996, 55, 491.	1.7	97
241	Inhibition of amyloid-Î² plaque formation by Î±-synuclein. Nature Medicine, 2015, 21, 802-807.	30.7	97
242	Trafficking of adenoâ€associated virus vectors across a model of the bloodâ€“brain barrier; a comparative study of transcytosis and transduction using primary human brain endothelial cells. Journal of Neurochemistry, 2017, 140, 216-230.	3.9	97
243	Neuronal Structure is Altered by Amyloid Plaques. Reviews in the Neurosciences, 2004, 15, 267-278.	2.9	96
244	Studying synapses in human brain with array tomography and electron microscopy. Nature Protocols, 2013, 8, 1366-1380.	12.0	95
245	GROÎ±/KC, a chemokine receptor CXCR2 ligand, can be a potent trigger for neuronal ERK1/2 and PI-3 kinase pathways and for tau hyperphosphorylationâ€”a role in Alzheimer's disease?. Journal of Neuroimmunology, 2002, 122, 55-64.	2.3	94
246	Predicting the location of entorhinal cortex from MRI. NeuroImage, 2009, 47, 8-17.	4.2	94
247	Are Tangles as Toxic as They Look?. Journal of Molecular Neuroscience, 2011, 45, 438-444.	2.3	93
248	Inhibition of the NFAT Pathway Alleviates Amyloid Beta Neurotoxicity in a Mouse Model of Alzheimer's Disease. Journal of Neuroscience, 2012, 32, 3176-3192.	3.6	92
249	Tau Antibody Targeting Pathological Species Blocks Neuronal Uptake and Interneuron Propagation of Tau inÂVitro. American Journal of Pathology, 2017, 187, 1399-1412.	3.8	92
250	Somatic genomic changes in single Alzheimerâ€™s disease neurons. Nature, 2022, 604, 714-722.	27.8	92
251	Comparison of transduction efficiency of recombinant AAV serotypes 1, 2, 5, and 8 in the rat nigrostriatal system. Journal of Neurochemistry, 2009, 109, 838-845.	3.9	91
252	Functional Alterations in AlzheimerÊ¼s Disease. Journal of Neuropathology and Experimental Neurology, 1995, 54, 38-41.	1.7	90

#	Article	IF	Citations
253	Ubiquilin 1 Modulates Amyloid Precursor Protein Trafficking and AÎ² Secretion. Journal of Biological Chemistry, 2006, 281, 32240-32253.	3.4	90
254	The nuclear membrane organization of leukotriene synthesis. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 20434-20439.	7.1	90
255	Adult Onset Leukodystrophy with Neuroaxonal Spheroids: Clinical, Neuroimaging and Neuropathologic Observations. Brain Pathology, 2009, 19, 39-47.	4.1	90
256	Mild to moderate Alzheimer dementia with insufficient neuropathological changes. Annals of Neurology, 2014, 75, 597-601.	5.3	90
257	Preoperative Cognitive Stratification of Older Elective Surgical Patients: A Cross-Sectional Study. Anesthesia and Analgesia, 2016, 123, 186-192.	2.2	90
258	Shared genetic risk between corticobasal degeneration, progressive supranuclear palsy, and frontotemporal dementia. Acta Neuropathologica, 2017, 133, 825-837.	7.7	90
259	Synaptic phosphorylated Î±-synuclein in dementia with Lewy bodies. Brain, 2017, 140, 3204-3214.	7.6	90
260	Apolipoprotein E Receptors Mediate Neurite Outgrowth through Activation of p44/42 Mitogen-activated Protein Kinase in Primary Neurons. Journal of Biological Chemistry, 2004, 279, 34948-34956.	3.4	89
261	Decreased Catalytic Activity of the Insulin-degrading Enzyme in Chromosome 10-Linked Alzheimer Disease Families. Journal of Biological Chemistry, 2007, 282, 7825-7832.	3.4	89
262	Examination of the Clinicopathologic Continuum of Alzheimer Disease in the Autopsy Cohort of the National Alzheimer Coordinating Center. Journal of Neuropathology and Experimental Neurology, 2013, 72, 1182-1192.	1.7	89
263	Seedâ€competent highâ€molecularâ€weight tau species accumulates in the cerebrospinal fluid of Alzheimer's disease mouse model and human patients. Annals of Neurology, 2016, 80, 355-367.	5.3	89
264	Plaque-Induced Abnormalities in Neurite Geometry in Transgenic Models of Alzheimer Disease: Implications for Neural System Disruption. Journal of Neuropathology and Experimental Neurology, 2001, 60, 753-758.	1.7	88
265	The membrane organization of leukotriene synthesis. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 6587-6592.	7.1	88
266	Distinct Pools of Î²-Amyloid in Alzheimer Diseaseâ€“Affected Brain. Archives of Neurology, 2008, 65, 906-12.	4.5	88
267	Soluble pathological tau in the entorhinal cortex leads to presynaptic deficits in an early Alzheimerâ€™s disease model. Acta Neuropathologica, 2014, 127, 257-270.	7.7	88
268	Shorter Telomeres May Mark Early Risk of Dementia: Preliminary Analysis of 62 Participants from the Nurses' Health Study. PLoS ONE, 2008, 3, e1590.	2.5	87
269	Temporal T807 binding correlates with CSF tau and phospho-tau in normal elderly. Neurology, 2016, 87, 920-926.	1.1	86
270	Apolipoprotein E modulates Î³â€secretase cleavage of the amyloid precursor protein. Journal of Neurochemistry, 2004, 90, 1132-1143.	3.9	85

#	Article	IF	Citations
271	Plaque-Derived Oxidative Stress Mediates Distorted Neurite Trajectories in the Alzheimer Mouse Model. Journal of Neuropathology and Experimental Neurology, 2006, 65, 1082-1089.	1.7	85
272	Plasma Amyloid Î²-Protein and C-reactive Protein in Relation to the Rate of Progression of Alzheimer Disease. Archives of Neurology, 2008, 65, 776-85.	4.5	84
273	Propagation of tau pathology in Alzheimerâ€™s disease: identification of novel therapeutic targets. Alzheimer's Research and Therapy, 2013, 5, 49.	6.2	84
274	Tau reduction in the presence of amyloid-Î² prevents tau pathology and neuronal death in vivo. Brain, 2018, 141, 2194-2212.	7.6	84
275	Autoantibodies to Redox-modified Oligomeric AÎ² Are Attenuated in the Plasma of Alzheimer's Disease Patients. Journal of Biological Chemistry, 2005, 280, 17458-17463.	3.4	83
276	Microtubule-Affinity Regulating Kinase (MARK) Is Tightly Associated with Neurofibrillary Tangles in Alzheimer Brain: A Fluorescence Resonance Energy Transfer Study. Journal of Neuropathology and Experimental Neurology, 2000, 59, 966-971.	1.7	82
277	Detection of novel intracellular Oâ€synuclein oligomeric species by fluorescence lifetime imaging. FASEB Journal, 2006, 20, 2050-2057.	0.5	82
278	Multisite assessment of NIAâ€AA guidelines for the neuropathologic evaluation of Alzheimer's disease. Alzheimer's and Dementia, 2016, 12, 164-169.	0.8	82
279	Human tau increases amyloid Î² plaque size but not amyloid Î²â€mediated synapse loss in a novel mouse model of Alzheimer's disease. European Journal of Neuroscience, 2016, 44, 3056-3066.	2.6	81
280	Characterization of the 18 kDa translocator protein (TSPO) expression in postâ€mortem normal and Alzheimer's disease brains. Brain Pathology, 2020, 30, 151-164.	4.1	81
281	Apolipoprotein E ?4 allele is not associated with earlier age at onset in amyotrophic lateral sclerosis. Annals of Neurology, 1995, 38, 460-463.	5.3	80
282	Calcineurin inhibition with FK506 ameliorates dendritic spine density deficits in plaque-bearing Alzheimer model mice. Neurobiology of Disease, 2011, 41, 650-654.	4.4	80
283	Alzheimerâ€™s Disease Biomarkers and Future Decline in Cognitive Normal Older Adults. Journal of Alzheimer's Disease, 2017, 60, 1451-1459.	2.6	80
284	Polygenic hazard score: an enrichment marker for Alzheimerâ€™s associated amyloid and tau deposition. Acta Neuropathologica, 2018, 135, 85-93.	7.7	80
285	A direct demonstration of the perforant pathway terminal zone in Alzheimer's disease using the monoclonal antibody Alz-50. Brain Research, 1988, 450, 392-397.	2.2	79
286	A highly insoluble state of AÎ² similar to that of Alzheimer's disease brain is found in Arctic APP transgenic mice. Neurobiology of Aging, 2009, 30, 1393-1405.	3.1	79
287	Frequent and symmetric deposition of misfolded tau oligomers within presynaptic and postsynaptic terminals in Alzheimerâ€™s disease. Acta Neuropathologica Communications, 2014, 2, 146.	5.2	79
288	Secretion and Uptake of Î±-Synuclein Via Extracellular Vesicles in Cultured Cells. Cellular and Molecular Neurobiology, 2018, 38, 1539-1550.	3.3	79

#	Article	IF	Citations
289	A highly sensitive novel immunoassay specifically detects low levels of soluble AÎ² oligomers in human cerebrospinal fluid. Alzheimer's Research and Therapy, 2015, 7, 14.	6.2	78
290	Stereology: A Practical Primer for Neuropathology. Journal of Neuropathology and Experimental Neurology, 1998, 57, 305-310.	1.7	77
291	LRP and senile plaques in Alzheimerâ€™s disease: colocalization with apolipoprotein E and with activated astrocytes. Molecular Brain Research, 2002, 104, 38-46.	2.3	77
292	Quantification of neurons in Alzheimer and control brains with ex vivo high resolution magic angle spinning proton magnetic resonance spectroscopy and stereology. Magnetic Resonance Imaging, 2002, 20, 527-533.	1.8	75
293	Senile dementia associated with amyloid Î² protein angiopathy and tau perivascular pathology but not neuritic plaques in patients homozygous for the APOE-Îµ4 allele. Acta Neuropathologica, 2000, 100, 1-12.	7.7	74
294	Soluble tau Species, Not Neurofibrillary Aggregates, Disrupt Neural System Integration in a tau Transgenic Model. Journal of Neuropathology and Experimental Neurology, 2011, 70, 588-595.	1.7	74
295	Clinical, Pathological, and Biochemical Spectrum of Alzheimer Disease Associated With PS-1 Mutations. American Journal of Geriatric Psychiatry, 2004, 12, 146-156.	1.2	73
296	The Challenge of Connecting the Dots in the B.R.A.I.N.. Neuron, 2013, 80, 270-274.	8.1	73
297	Plaque-Associated Local Toxicity Increases over the Clinical Course of Alzheimer Disease. American Journal of Pathology, 2016, 186, 375-384.	3.8	73
298	Allosteric Modulation of PS1/Î³-Secretase Conformation Correlates with Amyloid Î²42/40 Ratio. PLoS ONE, 2009, 4, e7893.	2.5	73
299	Cerebrovascular Pathology Contributes to the Heterogeneity of Alzheimer's Disease. Journal of Alzheimer's Disease, 1998, 1, 119-134.	2.6	72
300	TAR-DNA Binding Protein 43 in Pick Disease. Journal of Neuropathology and Experimental Neurology, 2008, 67, 62-67.	1.7	72
301	Different tau species lead to heterogeneous tau pathology propagation and misfolding. Acta Neuropathologica Communications, 2018, 6, 132.	5.2	72
302	AÎ² Associated Neuropil Changes. Journal of Neuropathology and Experimental Neurology, 1998, 57, 1122-1130.	1.7	71
303	Notch1 and Amyloid Precursor Protein Are Competitive Substrates for Presenilin1-dependent Î³-Secretase Cleavage. Journal of Biological Chemistry, 2001, 276, 30018-30023.	3.4	71
304	Heparan Sulfate Accumulation with AÎ² Deposits in Alzheimer's Disease and Tg2576 Mice is Contributed by Glial Cells. Brain Pathology, 2008, 18, 548-561.	4.1	71
305	AÎ² alters the connectivity of olfactory neurons in the absence of amyloid plaques in vivo. Nature Communications, 2012, 3, 1009.	12.8	71
306	In vivo rate-determining steps of tau seed accumulation in Alzheimerâ€™s disease. Science Advances, 2021, 7, eabh1448.	10.3	70

#	Article	IF	Citations
307	Kinetics of Cerebral Amyloid Angiopathy Progression in a Transgenic Mouse Model of Alzheimer Disease. Journal of Neuroscience, 2006, 26, 365-371.	3.6	69
308	Tangle-Bearing Neurons Survive Despite Disruption of Membrane Integrity in a Mouse Model of Tauopathy. Journal of Neuropathology and Experimental Neurology, 2009, 68, 757-761.	1.7	69
309	Alzheimer's Diseaseâ€Associated Ubiquilinâ€1 Regulates Presenilinâ€1 Accumulation and Aggresome Formation. Traffic, 2011, 12, 330-348.	2.7	69
310	Association between Î±-synuclein blood transcripts and early, neuroimaging-supported Parkinsonâ€™s disease. Brain, 2015, 138, 2659-2671.	7.6	69
311	Î±2-Macroglobulin Exposure Reduces Calcium Responses to N-Methyl-d-Aspartate via Low Density Lipoprotein Receptor-related Protein in Cultured Hippocampal Neurons. Journal of Biological Chemistry, 2002, 277, 14458-14466.	3.4	68
312	Pharmacological inhibition of PARP-1 reduces Î±-synuclein- and MPP+-induced cytotoxicity in Parkinsonâ€™s disease in vitro models. Biochemical and Biophysical Research Communications, 2007, 357, 596-602.	2.1	67
313	Thal Amyloid Stages Do Not Significantly Impact the Correlation Between Neuropathological Change and Cognition in the Alzheimer Disease Continuum. Journal of Neuropathology and Experimental Neurology, 2016, 75, 516-526.	1.7	67
314	Alzheimer's mutation. Nature, 1991, 350, 564-564.	27.8	66
315	Colocalization and Fluorescence Resonance Energy Transfer between cdk5 and AT8 Suggests a Close Association in Pre-Neurofibrillary Tangles and Neurofibrillary Tangles. Journal of Neuropathology and Experimental Neurology, 2002, 61, 557-564.	1.7	66
316	Passive immunotherapy rapidly increases structural plasticity in a mouse model of Alzheimer disease. Neurobiology of Disease, 2009, 33, 213-220.	4.4	66
317	Apolipoprotein E: Isoform Specific Differences in Tertiary Structure and Interaction with Amyloid-Î² in Human Alzheimer Brain. PLoS ONE, 2011, 6, e14586.	2.5	66
318	The Role of Clusterin in Amyloid-Î²â€“Associated Neurodegeneration. JAMA Neurology, 2014, 71, 180.	9.0	66
319	Developmental Regulation of Presenilin mRNA Expression Parallels Notch Expression. Journal of Neuropathology and Experimental Neurology, 1997, 56, 40-44.	1.7	65
320	Interaction of Î±-synuclein and synphilin-1: effect of Parkinson's disease-associated mutations. Journal of Neurochemistry, 2001, 77, 929-934.	3.9	65
321	Transcriptional and conformational changes of the tau molecule in Alzheimer's disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2005, 1739, 150-157.	3.8	65
322	Characterization of Oligomer Formation of Amyloid-Î² Peptide Using a Split-luciferase Complementation Assay. Journal of Biological Chemistry, 2011, 286, 27081-27091.	3.4	65
323	A Food and Drug Administration-approved Asthma Therapeutic Agent Impacts Amyloid Î² in the Brain in a Transgenic Model of Alzheimer Disease. Journal of Biological Chemistry, 2015, 290, 1966-1978.	3.4	65
324	Non-Fibrillar Oligomeric Amyloid-Î² within Synapses. Journal of Alzheimer's Disease, 2016, 53, 787-800.	2.6	65

#	Article	IF	Citations
325	Pathologic Changes in the Olfactory System in Aging and Alzheimer's Diseasea. Annals of the New York Academy of Sciences, 1991, 640, 14-19.	3.8	64
326	MPP+Induced Substantia Nigra Degeneration Is Attenuated in nNOS Knockout Mice. Neurobiology of Disease, 1997, 4, 114-121.	4.4	63
327	Polygenic hazard score, amyloid deposition and Alzheimerâ€™s neurodegeneration. Brain, 2019, 142, 460-470.	7.6	63
328	Preoperative Cognitive Assessment of the Elderly Surgical Patient. Anesthesiology, 2011, 114, 1265-1268.	2.5	63
329	Alteration in the pattern of nerve terminal protein immunoreactivity in the perforant pathway in Alzheimer's disease and in rats after entorhinal lesions. Neurobiology of Aging, 1992, 13, 283-291.	3.1	62
330	Î²-Site APP Cleaving Enzyme mRNA Expression in APP Transgenic Mice. American Journal of Pathology, 2001, 158, 173-177.	3.8	62
331	Plasma AÎ² Levels Do Not Reflect Brain AÎ² Levels. Journal of Neuropathology and Experimental Neurology, 2007, 66, 264-271.	1.7	62
332	Transcriptional dysregulation in a transgenic model of Parkinson disease. Neurobiology of Disease, 2008, 29, 515-528.	4.4	62
333	Demonstration by Fluorescence Resonance Energy Transfer of a Close Association Between Activated MAP Kinase and Neurofibrillary Tangles: Implications for MAP Kinase Activation in Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 1999, 58, 1090-1098.	1.7	61
334	Identification of neurotoxic cytokines by profiling Alzheimerâ€™s disease tissues and neuron culture viability screening. Scientific Reports, 2015, 5, 16622.	3.3	61
335	Neuroethics Guiding Principles for the NIH BRAIN Initiative. Journal of Neuroscience, 2018, 38, 10586-10588.	3.6	61
336	Apolipoprotein E Genotype and Deposits of AÎ²40 and AÎ²42 in Alzheimer Disease. Archives of Neurology, 1998, 55, 1001.	4.5	60
337	Single molecule profiling of tau gene expression in Alzheimerâ€™s disease. Journal of Neurochemistry, 2007, 103, 1228-1236.	3.9	60
338	Mild cholesterol depletion reduces amyloidâ€Î²2 production by impairing APP trafficking to the cell surface. Journal of Neurochemistry, 2009, 110, 220-230.	3.9	60
339	A Luminex Assay Detects Amyloid Î² Oligomers in Alzheimerâ€™s Disease Cerebrospinal Fluid. PLoS ONE, 2013, 8, e67898.	2.5	59
340	Dopamine-Induced Conformational Changes in Alpha-Synuclein. PLoS ONE, 2009, 4, e6906.	2.5	59
341	Low Density Lipoprotein Receptor-related Protein (LRP) Interacts with Presenilin 1 and Is a Competitive Substrate of the Amyloid Precursor Protein (APP) for Î³-Secretase. Journal of Biological Chemistry, 2005, 280, 27303-27309.	3.4	57
342	Effects of Simvastatin on Cholesterol Metabolism and Alzheimer Disease Biomarkers. Alzheimer Disease and Associated Disorders, 2010, 24, 220-226.	1.3	57

#	Article	IF	Citations
343	Brain interstitial oligomeric amyloid Î² increases with age and is resistant to clearance from brain in a mouse model of Alzheimer's disease. FASEB Journal, 2013, 27, 3239-3248.	0.5	57
344	Regional Variation in the Distribution of Apolipoprotein E and AÎ² in AlzheimerÊ¼s Disease. Journal of Neuropathology and Experimental Neurology, 1995, 54, 833-841.	1.7	56
345	GGA1 Acts as a Spatial Switch Altering Amyloid Precursor Protein Trafficking and Processing. Journal of Neuroscience, 2006, 26, 9913-9922.	3.6	56
346	Structural Interactions between Inhibitor and Substrate Docking Sites Give Insight into Mechanisms of Human PS1 Complexes. Structure, 2014, 22, 125-135.	3.3	56
347	Meta-analysis of mouse transcriptomic studies supports a context-dependent astrocyte reaction in acute CNS injury versus neurodegeneration. Journal of Neuroinflammation, 2020, 17, 227.	7.2	56
348	Alpha-Synuclein and Chaperones in Dementia With Lewy Bodies. Journal of Neuropathology and Experimental Neurology, 2005, 64, 1058-1066.	1.7	55
349	Clinical and biochemical correlates of insoluble Î±-synuclein in dementia with Lewy bodies. Acta Neuropathologica, 2006, 111, 101-108.	7.7	55
350	An Investigation of Clinical Correlates of Lewy Bodies in Autopsy-Proven Alzheimer Disease. Archives of Neurology, 2001, 58, 460-5.	4.5	54
351	Progression of Cerebral Amyloid Angiopathy in Transgenic Mouse Models of Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 2005, 64, 588-594.	1.7	54
352	Coordinated Expression of Caspase 8, 3 and 7 mRNA in Temporal Cortex of Alzheimer Disease: Relationship to Formic Acid Extractable AÎ²42 Levels. Journal of Neuropathology and Experimental Neurology, 2006, 65, 508-515.	1.7	54
353	A Reporter of Local Dendritic Translocation Shows Plaque- Related Loss of Neural System Function in APP-Transgenic Mice. Journal of Neuroscience, 2009, 29, 12636-12640.	3.6	54
354	Distinct Dendritic Spine and Nuclear Phases of Calcineurin Activation after Exposure to Amyloid-Î² Revealed by a Novel Fluorescence Resonance Energy Transfer Assay. Journal of Neuroscience, 2012, 32, 5298-5309.	3.6	54
355	Systematic review and meta-analysis of human transcriptomics reveals neuroinflammation, deficient energy metabolism, and proteostasis failure across neurodegeneration. Neurobiology of Disease, 2021, 149, 105225.	4.4	54
356	Association of membrane-bound amyloid precursor protein APP with the apolipoprotein E receptor LRP. Molecular Brain Research, 2001, 87, 238-245.	2.3	53
357	Î±-Synuclein in Extracellular Vesicles: Functional Implications and Diagnostic Opportunities. Cellular and Molecular Neurobiology, 2016, 36, 437-448.	3.3	53
358	Spread of tau down neural circuits precedes synapse and neuronal loss in the rTgTauEC mouse model of early <scp>A</scp>lzheimer's disease. Synapse, 2017, 71, e21965.	1.2	53
359	Accumulation of N-3 Polyunsaturated Fatty Acids by Cultured Human Y79 Retinoblastoma Cells. Journal of Neurochemistry, 1981, 37, 60-69.	3.9	52
360	Serine and Threonine Phosphorylation of the Low Density Lipoprotein Receptor-related Protein by Protein Kinase CÎ± Regulates Endocytosis and Association with Adaptor Molecules. Journal of Biological Chemistry, 2004, 279, 40536-40544.	3.4	52

#	Article	IF	Citations
361	Converse modulation of toxic Î±-synuclein oligomers in living cells by Nâ€²-benzylidene-benzohydrazide derivates and ferric iron. Biochemical and Biophysical Research Communications, 2010, 391, 461-466.	2.1	52
362	Synaptic Plasticity Defect Following Visual Deprivation in Alzheimer's Disease Model Transgenic Mice. Journal of Neuroscience, 2012, 32, 8004-8011.	3.6	52
363	Partial reduction of microglia does not affect tau pathology in aged mice. Journal of Neuroinflammation, 2018, 15, 311.	7.2	52
364	Regulation of tau internalization, degradation, and seeding by LRP1 reveals multiple pathways for tau catabolism. Journal of Biological Chemistry, 2021, 296, 100715.	3.4	52
365	APOE4 derived from astrocytes leads to bloodâ€“brain barrier impairment. Brain, 2022, 145, 3582-3593.	7.6	52
366	Detection of Myelination Using a Novel Histological Probe. Journal of Histochemistry and Cytochemistry, 2005, 53, 1511-1516.	2.5	51
367	Regional Cortical Thinning and Cerebrospinal Biomarkers Predict Worsening Daily Functioning Across the Alzheimer's Disease Spectrum. Journal of Alzheimer's Disease, 2014, 41, 719-728.	2.6	51
368	Absence of Alzheimer Disease Neuropathologic Changes in Eyes of Subjects With Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 2017, 76, 376-383.	1.7	50
369	Pro-cathepsin D interacts with the extracellular domain of the Î² chain of LRP1 and promotes LRP1-dependent fibroblast outgrowth. Journal of Cell Science, 2010, 123, 3336-3346.	2.0	49
370	Formation, release, and internalization of stable tau oligomers in cells. Journal of Neurochemistry, 2016, 139, 1163-1174.	3.9	49
371	Polygenic hazard scores in preclinical Alzheimer disease. Annals of Neurology, 2017, 82, 484-488.	5.3	49
372	In Vivo Imaging of Î±-Synuclein in Mouse Cortex Demonstrates Stable Expression and Differential Subcellular Compartment Mobility. PLoS ONE, 2010, 5, e10589.	2.5	49
373	Choline Uptake in Cultured Human Y79 Retinoblastoma Cells: Effect of Polyunsaturated Fatty Acid Compositional Modifications. Journal of Neurochemistry, 1982, 38, 650-656.	3.9	48
374	Amyloid structure exhibits polymorphism on multiple length scales in human brain tissue. Scientific Reports, 2016, 6, 33079.	3.3	48
375	Fyn Modulation of Dab1 Effects on Amyloid Precursor Protein and ApoE Receptor 2 Processing. Journal of Biological Chemistry, 2008, 283, 6288-6299.	3.4	47
376	Tau Prion-Like Propagation: State of theÂArt and Current Challenges. Advances in Experimental Medicine and Biology, 2019, 1184, 305-325.	1.6	47
377	Role of Apolipoprotein E in Î²-Amyloidogenesis. Journal of Biological Chemistry, 2015, 290, 15163-15174.	3.4	46
378	Î²-Amyloid Induces Pathology-Related Patterns of Tau Hyperphosphorylation at Synaptic Terminals. Journal of Neuropathology and Experimental Neurology, 2018, 77, 814-826.	1.7	46

#	Article	IF	Citations
379	Notch1 Competes with the Amyloid Precursor Protein for Î³-Secretase and Down-regulates Presenilin-1 Gene Expression. Journal of Biological Chemistry, 2003, 278, 47370-47375.	3.4	45
380	Mutations in amyloid precursor protein affect its interactions with presenilin/Î³-secretase. Molecular and Cellular Neurosciences, 2009, 41, 166-174.	2.2	45
381	Regulation of Dynamin Oligomerization in Cells: The Role of Dynaminâ€“Actin Interactions and Its <scp>GTPase</scp> Activity. Traffic, 2014, 15, 819-838.	2.7	45
382	Cerebrovascular Senescence Is Associated With Tau Pathology in Alzheimer's Disease. Frontiers in Neurology, 2020, 11, 575953.	2.4	45
383	Neuropathology of Alzheimer's Disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2008, 89, 233-243.	1.8	44
384	A single amino acid substitution differentiates Hsp70-dependent effects on Î±-synuclein degradation and toxicity. Biochemical and Biophysical Research Communications, 2004, 325, 367-373.	2.1	43
385	Alzheimer Disease Therapeutics. Journal of Neuropathology and Experimental Neurology, 2001, 60, 923-928.	1.7	42
386	Reversal of Neurofibrillary Tangles and Tau-Associated Phenotype in the rTgTauEC Model of Early Alzheimer's Disease. Journal of Neuroscience, 2013, 33, 13300-13311.	3.6	42
387	Current directions in tau research: Highlights from Tau 2020. Alzheimer's and Dementia, 2022, 18, 988-1007.	0.8	42
388	No alteration in tau exon 10 alternative splicing in tangle-bearing neurons of the Alzheimerâ€™s disease brain. Acta Neuropathologica, 2006, 112, 439-449.	7.7	41
389	Stable Size Distribution of Amyloid Plaques Over the Course of Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 2012, 71, 694-701.	1.7	41
390	Rarity of the Alzheimer Diseaseâ€“ProtectiveAPPA673T Variant in the United States. JAMA Neurology, 2015, 72, 209.	9.0	41
391	Subjective Cognitive Decline Is Associated With Altered Default Mode Network Connectivity in Individuals With a Family History of Alzheimerâ€™s Disease. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2018, 3, 463-472.	1.5	41
392	Unraveling the Mystery of Cognitive Changes in Old Age: Correlation of Neuropsychological Evaluation With Neuropathological Findings in the Extreme Old. International Psychogeriatrics, 1998, 10, 25-41.	1.0	40
393	A limited role for microglia in antibody mediated plaque clearance in APP mice. Neurobiology of Disease, 2007, 28, 286-292.	4.4	40
394	Calcineurin inhibition with systemic FK506 treatment increases dendritic branching and dendritic spine density in healthy adult mouse brain. Neuroscience Letters, 2011, 487, 260-263.	2.1	40
395	Tau Propagation, Different Tau Phenotypes, and Prion-like Properties of Tau. Neuron, 2014, 82, 1189-1190.	8.1	40
396	Systematic review of human postâ€mortem immunohistochemical studies and bioinformatics analyses unveil the complexity of astrocyte reaction in Alzheimer's disease. Neuropathology and Applied Neurobiology, 2022, 48, .	3.2	40

#	Article	IF	Citations
397	Immunohistochemical and in situ analysis of amyloid precursor-like protein-1 and amyloid precursor-like protein-2 expression in Alzheimer disease and aged control brains. Brain Research, 1998, 804, 45-51.	2.2	39
398	LRAD3, A Novel Low-Density Lipoprotein Receptor Family Member That Modulates Amyloid Precursor Protein Trafficking. Journal of Neuroscience, 2011, 31, 10836-10846.	3.6	39
399	Topological analyses in APP/PS1 mice reveal that astrocytes do not migrate to amyloid-Î² plaques. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 15556-15561.	7.1	39
400	THE FEASIBILITY OF AT-HOME IPAD COGNITIVE TESTING FOR USE IN CLINICAL TRIALS. journal of prevention of Alzheimer's disease, The, 2016, 3, 1-5.	2.7	39
401	Cellular specificity and regional distribution of amyloid Î² protein precursor alternative transcripts are unaltered in Alzheimer hippocampal formation. Molecular Brain Research, 1993, 18, 246-252.	2.3	38
402	Lack of independent associations of apolipoprotein E promoter and intron 1 polymorphisms with Alzheimer's disease. Neuroscience Letters, 1999, 272, 155-158.	2.1	38
403	Caspase activation without apoptosis: insight into AÎ² initiation of neurodegeneration. Nature Neuroscience, 2011, 14, 5-6.	14.8	38
404	Tau Causes Synapse Loss without Disrupting Calcium Homeostasis in the rTg4510 Model of Tauopathy. PLoS ONE, 2013, 8, e80834.	2.5	38
405	Dementia with Lewy Bodies. Journal of the American Geriatrics Society, 1998, 46, 1449-1458.	2.6	37
406	Uptake of fibrillar Î²-amyloid by microglia isolated from MSR-A (type I and type II) knockout mice. NeuroReport, 2001, 12, 1151-1154.	1.2	37
407	RNA Aptamer Probes as Optical Imaging Agents for the Detection of Amyloid Plaques. PLoS ONE, 2014, 9, e89901.	2.5	37
408	Elevation of LDL Receptor-Related protein Levels via Ligand Interactions in Alzheimer Disease and In Vitro. Journal of Neuropathology and Experimental Neurology, 2001, 60, 430-440.	1.7	36
409	Lack of association of the cholesterol 24-hydroxylase (CYP46) intron 2 polymorphism with Alzheimerâ€™s disease. Neuroscience Letters, 2004, 367, 228-231.	2.1	36
410	Increase in the relative expression of tau with four microtubule binding repeat regions in frontotemporal lobar degeneration and progressive supranuclear palsy brains. Acta Neuropathologica, 2007, 114, 471-479.	7.7	36
411	Episodic memory of odors stratifies Alzheimer biomarkers in normal elderly. Annals of Neurology, 2016, 80, 846-857.	5.3	36
412	Apolipoprotein E4 Reduction with Antisense Oligonucleotides Decreases Neurodegeneration in a Tauopathy Model. Annals of Neurology, 2021, 89, 952-966.	5.3	36
413	Characterization of TauC3 antibody and demonstration of its potential to block tau propagation. PLoS ONE, 2017, 12, e0177914.	2.5	36
414	Neuritic alterations and neural system dysfunction in Alzheimer's disease and dementia with Lewy bodies. Neurochemical Research, 2003, 28, 1683-1691.	3.3	34

#	Article	IF	Citations
415	Association of APOE Genotype With Heterogeneity of Cognitive Decline Rate in Alzheimer Disease. Neurology, 2021, 96, e2414-e2428.	1.1	34
416	Glycine Uptake by Cultured Human Y79 Retinoblastoma Cells: Effect of Changes in Phospholipid Fatty Acid Unsaturation. Journal of Neurochemistry, 1983, 40, 70-78.	3.9	33
417	Cortical neurons expressing calcium binding proteins are spared in dementia with Lewy bodies. Acta Neuropathologica, 2001, 101, 36-42.	7.7	33
418	Mouse Gender Influences Brain Transduction by Intravascularly Administered AAV9. Molecular Therapy, 2013, 21, 1470-1471.	8.2	33
419	Methylene blue does not reverse existing neurofibrillary tangle pathology in the rTg4510 mouse model of tauopathy. Neuroscience Letters, 2014, 562, 63-68.	2.1	33
420	Cerebrospinal Fluid Particles in Alzheimer Disease and Parkinson Disease. Journal of Neuropathology and Experimental Neurology, 2015, 74, 672-687.	1.7	33
421	Identification of the novel activity-driven interaction between synaptotagmin 1 and presenilin 1 links calcium, synapse, and amyloid beta. BMC Biology, 2016, 14, 25.	3.8	33
422	A multifactorial model of pathology for age of onset heterogeneity in familial Alzheimerâ€™s disease. Acta Neuropathologica, 2021, 141, 217-233.	7.7	33
423	Visit-to-Visit Blood Pressure Variability, Neuropathology, and Cognitive Decline. Neurology, 2021, 96, e2812-e2823.	1.1	33
424	The pattern of NADPH-diaphorase staining, a marker of nitric oxide synthase activity, is altered in the perforant pathway terminal zone in Alzheimer's disease. Neuroscience Letters, 1993, 152, 165-168.	2.1	32
425	Localization of non-N-methyl-D-aspartate glutamate receptors in normal and Alzheimer hippocampal formation. Annals of Neurology, 1994, 35, 31-37.	5.3	32
426	Glutamate Receptor Dysregulation in the Hippocampus of Transgenic Mice Carrying Mutated Human Amyloid Precursor Protein. Neurobiology of Disease, 2001, 8, 90-102.	4.4	32
427	Antioxidants have a rapid and long-lasting effect on neuritic abnormalities in APP:PS1 mice. Neurobiology of Aging, 2010, 31, 2058-2068.	3.1	32
428	Neuronal activity and secreted amyloid Î² lead to altered amyloid Î² precursor protein and presenilin 1 interactions. Neurobiology of Disease, 2013, 50, 127-134.	4.4	32
429	Synaptic proteins associated with cognitive performance and neuropathology in older humans revealed by multiplexed fractionated proteomics. Neurobiology of Aging, 2021, 105, 99-114.	3.1	32
430	Pathogenic tau accelerates aging-associated activation of transposable elements in the mouse central nervous system. Progress in Neurobiology, 2022, 208, 102181.	5.7	32
431	Alpha-synuclein has an altered conformation and shows a tight intermolecular interaction with ubiquitin in Lewy bodies. Acta Neuropathologica, 2001, 102, 329-334.	7.7	31
432	An alternatively spliced form of rodent Î±-synuclein forms intracellular inclusions in vitro: role of the carboxy-terminus in Î±-synuclein aggregation. Neuroscience Letters, 2002, 323, 219-223.	2.1	31

#	Article	IF	Citations
433	Structural studies on the mechanism of protein aggregation in age related neurodegenerative diseases. Mechanisms of Ageing and Development, 2016, 156, 1-13.	4.6	31
434	Reversible Cation-Selective Attachment and Self-Assembly of Human Tau on Supported Brain Lipid Membranes. Nano Letters, 2018, 18, 3271-3281.	9.1	31
435	Persistent repression of tau in the brain using engineered zinc finger protein transcription factors. Science Advances, 2021, 7, .	10.3	31
436	Lack of association of trinucleotide repeat polymorphisms in the very-low-density lipoprotein receptor gene with Alzhelner's disease. Annals of Neurology, 1996, 39, 800-803.	5.3	30
437	APP substitutions V715F and L720P alter PS1 conformation and differentially affect AÎ² and AICD generation. Journal of Neurochemistry, 2005, 95, 446-456.	3.9	30
438	Entorhinal Cortex: Antemortem Cortical Thickness and Postmortem Neurofibrillary Tangles and Amyloid Pathology. American Journal of Neuroradiology, 2017, 38, 961-965.	2.4	30
439	Neurofibrillary Tangle Stage and the Rate of Progression of Alzheimer Symptoms. JAMA Neurology, 2017, 74, 540.	9.0	30
440	The NIH BRAIN Initiative: Integrating Neuroethics and Neuroscience. Neuron, 2019, 101, 394-398.	8.1	30
441	Alz-50 immunoreactivity in the thalamic reticular nucleus in Alzheimer's disease. Brain Research, 1990, 515, 227-234.	2.2	29
442	Risperidone Treatment of Behavioral Disturbances in Outpatients With Dementia. Journal of Neuropsychiatry and Clinical Neurosciences, 1999, 11, 336-342.	1.8	29
443	No evidence for genetic association or linkage of the cathepsin D (CTSD) exon 2 polymorphism and Alzheimer disease. Annals of Neurology, 2001, 49, 114-116.	5.3	29
444	Patterns of protein nitration in dementia with Lewy bodies and striatonigral degeneration. Acta Neuropathologica, 2002, 103, 495-500.	7.7	29
445	Rapid Notch1 Nuclear Translocation after Ligand Binding Depends on Presenilinâ€associated Î³â€Secretase Activity. Annals of the New York Academy of Sciences, 2000, 920, 223-226.	3.8	29
446	Physical and functional connection between auxilin and dynamin during endocytosis. EMBO Journal, 2006, 25, 4163-4174.	7.8	29
447	Carboxy Terminus Heat Shock Protein 70 Interacting Protein Reduces Tau-Associated Degenerative Changes. Journal of Alzheimer's Disease, 2015, 44, 937-947.	2.6	29
448	Effects of Ubiquilin 1 on the Unfolded Protein Response. Journal of Molecular Neuroscience, 2009, 38, 19-30.	2.3	28
449	Performance Characteristics of Plasma Amyloid-Î² 40 and 42 Assays. Journal of Alzheimer's Disease, 2009, 16, 277-285.	2.6	28
450	Tauâ€“amyloid interactions in the rTgTauEC model of early Alzheimer's disease suggest amyloidâ€induced disruption of axonal projections and exacerbated axonal pathology. Journal of Comparative Neurology, 2013, 521, 4236-4248.	1.6	28

#	Article	IF	Citations
451	Cholinergic modulation of hippocampal calcium activity across the sleep-wake cycle. ELife, 2019, 8, .	6.0	28
452	Neuroanatomical connections and specific regional vulnerability in Alzheimer's disease. Neurobiology of Aging, 1993, 14, 45-47.	3.1	27
453	CA3 neuronal degeneration follows chronic entorhinal cortex lesions. Neuroscience Letters, 1995, 197, 1-4.	2.1	27
454	Anti-superoxide dismutase antibodies are associated with survival in patients with sporadic amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2011, 12, 430-438.	2.1	27
455	Clustering of plaques contributes to plaque growth in a mouse model of Alzheimerâ€™s disease. Acta Neuropathologica, 2013, 126, 179-188.	7.7	27
456	Î²-Glucocerebrosidase activity in GBA -linked Parkinson disease. Neurology, 2020, 95, e685-e696.	1.1	27
457	Associations of Lower Caffeine Intake and Plasma Urate Levels with Idiopathic Parkinsonâ€™s Disease in the Harvard Biomarkers Study. Journal of Parkinson's Disease, 2020, 10, 505-510.	2.8	27
458	Genome-encoded cytoplasmic double-stranded RNAs, found in C9ORF72 ALS-FTD brain, propagate neuronal loss. Science Translational Medicine, 2021, 13, .	12.4	27
459	3D Visualization of the Temporal and Spatial Spread of Tau Pathology Reveals Extensive Sites of Tau Accumulation Associated with Neuronal Loss and Recognition Memory Deficit in Aged Tau Transgenic Mice. PLoS ONE, 2016, 11, e0159463.	2.5	27
460	Cerebral amyloid angiopathy and apolipoprotein E: Bad news for the good allele?. Annals of Neurology, 1997, 41, 701-702.	5.3	26
461	Effect of PS1 deficiency and an APP Î³-secretase inhibitor on Notch1 signaling in primary mammalian neurons. Molecular Brain Research, 2001, 87, 166-174.	2.3	26
462	Dynamic presenilin 1 and synaptotagmin 1 interaction modulates exocytosis and amyloid Î² production. Molecular Neurodegeneration, 2017, 12, 15.	10.8	26
463	Angiotensin II protects against Î±-synuclein toxicity and reduces protein aggregation in vitro. Biochemical and Biophysical Research Communications, 2007, 363, 846-851.	2.1	25
464	Hemianesthesia and Aphasia. Archives of Neurology, 1989, 46, 816.	4.5	24
465	Detection of presenilin-1 homodimer formation in intact cells using fluorescent lifetime imaging microscopy. Biochemical and Biophysical Research Communications, 2006, 340, 668-674.	2.1	24
466	Tau pathology does not affect experience-driven single-neuron and network-wide Arc/Arg3.1 responses. Acta Neuropathologica Communications, 2014, 2, 63.	5.2	24
467	Virus vector-mediated genetic modification of brain tumor stromal cells after intravenous delivery. Journal of Neuro-Oncology, 2018, 139, 293-305.	2.9	24
468	Risk of Transmissibility From Neurodegenerative Disease-Associated Proteins: Experimental Knowns and Unknowns. Journal of Neuropathology and Experimental Neurology, 2020, 79, 1141-1146.	1.7	24

#	Article	IF	Citations
469	PTEN activation contributes to neuronal and synaptic engulfment by microglia in tauopathy. Acta Neuropathologica, 2020, 140, 7-24.	7.7	24
470	Molecular Epidemiology of Alzheimer's Disease. New England Journal of Medicine, 1995, 333, 1283-1284.	27.0	23
471	Studying tau protein propagation and pathology in the mouse brain using adeno-associated viruses. Methods in Cell Biology, 2017, 141, 307-322.	1.1	23
472	Alzheimerâ€™s Disease: What Multiphoton Microscopy Teaches Us. Neuroscientist, 2002, 8, 386-390.	3.5	22
473	Nâ€cadherinâ€based adhesion enhances AÎ² release and decreases AÎ²_{42/40} ratio. Journal of Neurochemistry, 2009, 108, 350-360.	3.9	22
474	Systematic in silico analysis of clinically tested drugs for reducing amyloidâ€beta plaque accumulation in Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, 1487-1498.	0.8	22
475	Low-density lipoprotein receptor-related protein levels and endocytic function are reduced by overexpression of the FE65 adaptor protein, FE65L1. Journal of Neurochemistry, 2002, 82, 755-762.	3.9	21
476	Interaction between Presenilin 1 and Ubiquilin 1 as Detected by Fluorescence Lifetime Imaging Microscopy and a High-throughput Fluorescent Plate Reader. Journal of Biological Chemistry, 2006, 281, 26400-26407.	3.4	21
477	Association of SNCA with Parkinson: Replication in the Harvard NeuroDiscovery Center Biomarker Study. Movement Disorders, 2011, 26, 2283-2286.	3.9	21
478	Analysis of Î±-synuclein species enriched from cerebral cortex of humans with sporadic dementia with Lewy bodies. Brain Communications, 2020, 2, fcaa010.	3.3	21
479	Effects of aging on quinolinic acid lesions in rat striatum. Brain Research, 1991, 562, 276-280.	2.2	20
480	Functional alterations in neural circuits in Alzheimer's disease. Neurobiology of Aging, 1995, 16, 305-309.	3.1	20
481	Lack of allelic imbalance in APOE ïµ 3/4 brain mRNA expression in Alzheimer's disease. Neuroscience Letters, 1999, 272, 83-86.	2.1	20
482	A single dose of passive immunotherapy has extended benefits on synapses and neurites in an Alzheimer's disease mouse model. Brain Research, 2009, 1280, 178-185.	2.2	20
483	Isoform- and cell type-specific structure of apolipoprotein E lipoparticles as revealed by a novel Forster resonance energy transfer assay. Journal of Biological Chemistry, 2017, 292, 14720-14729.	3.4	20
484	Genome-wide association study and functional validation implicates JADE1 in tauopathy. Acta Neuropathologica, 2022, 143, 33-53.	7.7	19
485	Glycogen synthase kinase 3Î± and 3Î² do not colocalize with neurofibrillary tangles. Neurobiology of Aging, 1996, 17, 343-348.	3.1	18
486	Alzheimer's disease or Alzheimer's diseases? clues from molecular epidemiology. Annals of Neurology, 1996, 40, 135-136.	5.3	18

#	Article	IF	Citations
487	Evidence against association of the FE65 gene (APBB1) intron 13 polymorphism in Alzheimer's patients. Neuroscience Letters, 2000, 296, 17-20.	2.1	18
488	Disordered proteins in dementia. Annals of Medicine, 2002, 34, 259-271.	3.8	18
489	Activated Notch1 associates with a presenilin-1/Î³-secretase docking site. Journal of Neurochemistry, 2004, 87, 843-850.	3.9	18
490	Novel methods for integration and visualization of genomics and genetics data in Alzheimer's disease. Alzheimer's and Dementia, 2019, 15, 788-798.	0.8	18
491	Pathogenic PS1 phosphorylation at Ser367. ELife, 2017, 6, .	6.0	18
492	Targeting Tau Mitigates Mitochondrial Fragmentation and Oxidative Stress in Amyotrophic Lateral Sclerosis. Molecular Neurobiology, 2022, 59, 683-702.	4.0	18
493	The Influence of Vascular Risk Factors and Stroke on Cognition in Late Life. Alzheimer Disease and Associated Disorders, 2015, 29, 287-293.	1.3	17
494	The Golgi-Localized Î³-Ear-Containing ARF-Binding (GGA) Proteins Alter Amyloid-Î² Precursor Protein (APP) Processing through Interaction of Their GAE Domain with the Beta-Site APP Cleaving Enzyme 1 (BACE1). PLoS ONE, 2015, 10, e0129047.	2.5	17
495	Amyloidâ€beta oligomerization is associated with the generation of a typical peptide fragment fingerprint. Alzheimer's and Dementia, 2016, 12, 996-1013.	0.8	17
496	Fatty acid and lipid composition of the monkey retina in diet-induced hypercholesterolemia. Atherosclerosis, 1981, 40, 321-328.	0.8	15
497	Apolipoprotein E, AÎ², and Alzheimer Disease. An Editorial Comment. Journal of Neuropathology and Experimental Neurology, 1994, 53, 427-428.	1.7	15
498	The SIST-M. Alzheimer Disease and Associated Disorders, 2012, 26, 225-231.	1.3	15
499	Conformational fingerprinting of tau variants and strains by Raman spectroscopy. RSC Advances, 2021, 11, 8899-8915.	3.6	15
500	Novel genetic variants in MAPT and alterations in tau phosphorylation in amyotrophic lateral sclerosis postâ€mortem motor cortex and cerebrospinal fluid. Brain Pathology, 2022, 32, e13035.	4.1	15
501	Cyclic multiplex fluorescent immunohistochemistry and machine learning reveal distinct states of astrocytes and microglia in normal aging and Alzheimerâ€™s disease. Journal of Neuroinflammation, 2022, 19, 30.	7.2	15
502	Extracellular signal-regulated kinase (MAP kinase) immunoreactivity in the rhesus monkey brain. Neuroscience Letters, 1994, 166, 113-116.	2.1	14
503	Engulfment adapter PTB domain containing 1 interacts with and affects processing of the amyloid-Î² precursor protein. Neurobiology of Aging, 2012, 33, 732-743.	3.1	14
504	Direct Visualization of CHIP-Mediated Degradation of Alpha-Synuclein In Vivo: Implications for PD Therapeutics. PLoS ONE, 2014, 9, e92098.	2.5	14

#	Article	IF	Citations
505	Failure analysis of clinical trials to test the amyloid hypothesis. Annals of Neurology, 2014, 76, 159-161.	5.3	14
506	Neuronal calcineurin transcriptional targets parallel changes observed in Alzheimer disease brain. Journal of Neurochemistry, 2018, 147, 24-39.	3.9	14
507	Use of structural magnetic resonance imaging to predict who will get Alzheimer's disease. Annals of Neurology, 2000, 47, 430-439.	5.3	14
508	Statistical physics and Alzheimerâ€™s disease. Physica A: Statistical Mechanics and Its Applications, 1998, 249, 460-471.	2.6	13
509	Fluorescence lifetime imaging microscopy (FLIM) detects stimulus-dependent phosphorylation of the low density lipoprotein receptor-related protein (LRP) in primary neurons. Biochemical and Biophysical Research Communications, 2006, 349, 24-30.	2.1	13
510	Effect of APOE alleles on the glial transcriptome in normal aging and Alzheimerâ€™s disease. Nature Aging, 2021, 1, 919-931.	11.6	13
511	?2-Macroglobulin Receptor/Low Density Lipoprotein Receptor?Related Protein.. Annals of the New York Academy of Sciences, 1994, 737, 88-95.	3.8	12
512	Relation of Quantitative Indexes of Concurrent Î±-Synuclein Abnormalities to Clinical Outcome in Autopsy-Proven Alzheimer Disease. Archives of Neurology, 2006, 63, 226.	4.5	12
513	Studies of Amyloid Î²â€Protein Precursor Expression in Alzheimer's Disease. Annals of the New York Academy of Sciences, 1991, 640, 149-154.	3.8	11
514	Preclinical characterization of amyloid imaging probes with multiphoton microscopy. Journal of Alzheimer's Disease, 2006, 9, 401-407.	2.6	11
515	Endogenous Tau Aggregates in Oligodendrocytes of rTg4510 Mice Induced by Human P301L Tau. Journal of Alzheimer's Disease, 2013, 38, 589-600.	2.6	11
516	EM Structure of the Ectodomain of Integrin CD11b/CD18 and Localization of Its Ligand-Binding Site Relative to the Plasma Membrane. PLoS ONE, 2013, 8, e57951.	2.5	11
517	Measuring Caspase Activity In Vivo. Methods in Enzymology, 2014, 544, 251-269.	1.0	11
518	A flow cytometryâ€“based in vitro assay reveals that formation of apolipoprotein E (ApoE)â€“amyloid beta complexes depends on ApoE isoform and cell type. Journal of Biological Chemistry, 2018, 293, 13247-13256.	3.4	11
519	Differences in Assessment of Everyday Preferences Between People With Cognitive Impairment and Their Care Partners: The Role of Neuropsychiatric Symptoms. American Journal of Geriatric Psychiatry, 2020, 28, 1070-1078.	1.2	11
520	Plasma biomarkers for prognosis of cognitive decline in patients with mild cognitive impairment. Brain Communications, 2022, 4, .	3.3	11
521	Lack of association of presenilin-1 intron-8 polymorphism with neuropathological features of Alzheimer's disease. Brain Research, 1999, 816, 295-298.	2.2	10
522	Novel Progranulin Mutation Detected in 2 Patients With FTLD. Alzheimer Disease and Associated Disorders, 2011, 25, 173-178.	1.3	10

#	Article	IF	Citations
523	The Structured Interview & Scoring Toolâ€“Massachusetts Alzheimer's Disease Research Center (SIST-M). Archives of Neurology, 2011, 68, 343-50.	4.5	10
524	TheÂAlzheimer Disease-Causing Presenilin-1 L435F Mutation Causes Increased Production of Soluble AÎ²43 Species in Patient-Derived iPSC-Neurons, Closely Mimicking Matched Patient Brain Tissue. Journal of Neuropathology and Experimental Neurology, 2020, 79, 592-604.	1.7	10
525	Continuous Monitoring of Tau-Induced Neurotoxicity in Patient-Derived iPSC-Neurons. Journal of Neuroscience, 2021, 41, 4335-4348.	3.6	10
526	Calcineurin activation causes retinal ganglion cell degeneration. Molecular Vision, 2012, 18, 2828-38.	1.1	10
527	GERIATRIC BIOSCIENCE: Apolipoprotein E Genotype: Utility in Clinical Practice in Alzheimer's Disease. Journal of the American Geriatrics Society, 1996, 44, 1469-1471.	2.6	9
528	Tau at the Crossroads between Neurotoxicity and Neuroprotection. Neuron, 2017, 94, 703-704.	8.1	9
529	Effects of Species-Specific Genetics on Alzheimerâ€™s Mouse Models. Neuron, 2019, 101, 351-352.	8.1	9
530	Neuron numbers in Alzheimer's disease: Cell-specific pathology. Neurobiology of Aging, 1987, 8, 555-556.	3.1	8
531	Apolipoprotein <scp>E</scp> levels and <scp>A</scp>lzheimer risk. Annals of Neurology, 2015, 77, 204-205.	5.3	8
532	567. CRISPR-Cas9 Mediated Gene Editing in a Monogenic Form of Alzheimer's Disease. Molecular Therapy, 2016, 24, S226-S227.	8.2	8
533	An integrated genomic approach to dissect the genetic landscape regulating the cell-to-cell transfer of Î±-synuclein. Cell Reports, 2021, 35, 109189.	6.4	8
534	Impairment of visual cortical plasticity by amyloid-beta species. Neurobiology of Disease, 2021, 154, 105344.	4.4	8
535	Tau propagation is dependent on the genetic background of mouse strains. Brain Communications, 2022, 4, fcac048.	3.3	8
536	A NovelGRNMutation (GRNc.708+6_+9delTGAG) in Frontotemporal Lobar Degeneration With TDP-43â€“Positive Inclusions. Journal of Neuropathology and Experimental Neurology, 2014, 73, 467-473.	1.7	7
537	Massachusetts Alzheimer's Disease Research Center: Progress and challenges. Alzheimer's and Dementia, 2015, 11, 1241-1245.	0.8	7
538	Mutant torsinA in the heterozygous DYT1 state compromises HSV propagation in infected neurons and fibroblasts. Scientific Reports, 2018, 8, 2324.	3.3	7
539	Tau reduction in aged mice does not impact Microangiopathy. Acta Neuropathologica Communications, 2020, 8, 137.	5.2	7
540	Kinetics of tau aggregation reveals patient-specific tau characteristics among Alzheimerâ€™s cases. Brain Communications, 2021, 3, fcab096.	3.3	7

#	Article	IF	Citations
541	Lack of specific association of presenilin 1 (PS-1) protein with plaques and tangles in Alzheimer's disease. Journal of the Neurological Sciences, 1998, 158, 15-23.	0.6	6
542	The LDL receptor-related protein can form homo-dimers in neuronal cells. Neuroscience Letters, 2008, 442, 91-95.	2.1	6
543	Engulfment adaptor phosphotyrosine-binding-domain-containing 1 (GULP1) is a nucleocytoplasmic shuttling protein and is transactivationally active together with low-density lipoprotein receptor-related protein 1 (LRP1). Biochemical Journal, 2013, 450, 333-343.	3.7	6
544	Improved Design of Prodromal Alzheimer's Disease Trials through Cohort Enrichment and Surrogate Endpoints. Journal of Alzheimer's Disease, 2013, 36, 475-486.	2.6	6
545	APOEGenotype and Brain Development. JAMA Neurology, 2014, 71, 7.	9.0	6
546	Predictors of the importance of everyday preferences for older adults with cognitive impairment. International Psychogeriatrics, 2022, 34, 287-294.	1.0	6
547	Differential gene expression data from the human central nervous system across Alzheimer's disease, Lewy body diseases, and the amyotrophic lateral sclerosis and frontotemporal dementia spectrum. Data in Brief, 2021, 35, 106863.	1.0	6
548	Cytoplasmic Mislocalization of RNA Polymerase II Subunit RPB1 in Alzheimer Disease Is Linked to Pathologic Tau. Journal of Neuropathology and Experimental Neurology, 2021, 80, 530-540.	1.7	6
549	Heterogeneity of Tau Deposition and Microvascular Involvement in MCI and AD. Current Alzheimer Research, 2021, 18, 711-720.	1.4	6
550	Chapter 30 Functional integrity of neural systems related to memory in Alzheimer's disease. Progress in Brain Research, 1994, 100, 245-254.	1.4	5
551	Neuropathological markers of impaired cognition in the entorhinal cortex. Neurobiology of Aging, 1996, 17, 940-941.	3.1	5
552	Activity-Dependent Dysfunction in Visual and Olfactory Sensory Systems in Mouse Models of Down Syndrome. Journal of Neuroscience, 2017, 37, 9880-9888.	3.6	5
553	Characterizing Clinical and Neuropathological Traits of APOE Haplotypes in African Americans and Europeans. Journal of Alzheimer's Disease, 2020, 78, 467-477.	2.6	5
554	A Nuclear Magnetic Resonance Spectroscopy Method in Characterization of Blood Metabolomics for Alzheimerâ€™s Disease. Metabolites, 2022, 12, 181.	2.9	5
555	Quantitative Methods for the Detection of Tau Seeding Activity in Human Biofluids. Frontiers in Neuroscience, 2021, 15, 654176.	2.8	4
556	Computational Interspecies Translation Between Alzheimerâ€™s Disease Mouse Models and Human Subjects Identifies Innate Immune Complement, TYROBP, and TAM Receptor Agonist Signatures, Distinct From Influences of Aging. Frontiers in Neuroscience, 2021, 15, 727784.	2.8	4
557	Effects of Age and Ethnicity on the Link Between APOE Ïµ4 and Alzheimer Diseaseâ€”Reply. JAMA - Journal of the American Medical Association, 1998, 279, 581.	7.4	4
558	Longitudinal Changes in Neuropsychiatric Symptoms: Impact of Discrepancy in Everyday Preferences Between Persons With Cognitive Impairment and Their Care Partners. American Journal of Geriatric Psychiatry, 2022, 30, 619-623.	1.2	4

#	Article	IF	Citations
559	Mapping the Spatial Distribution of Fibrillar Polymorphs in Human Brain Tissue. Frontiers in Neuroscience, 2022, 16, .	2.8	4
560	Can the immune system fight Alzheimer disease?. Nature Medicine, 2006, 12, 755-756.	30.7	3
561	Longitudinal differences in everyday preferences: Comparisons between people with cognitive impairment and their care partners. International Journal of Geriatric Psychiatry, 2021, , .	2.7	3
562	P3-126: EXPLORATION OF PLASMA BIOMARKERS FOR ALZHEIMER'S DISEASE USING ISOTOPIC TANDEM MASS TAGS AND A COMBINED DIRECTED/DATA-DEPENDENT ACQUISITION NLC-MS/MS METHOD. , 2014, 10, P674-P674.		2
563	IC-P-162: Entorhinal, parahippocampal, and inferior temporal F18-T807 SUVR correlates with CSF total tau and tau T181P in cognitively normal elderly. , 2015, 11, P109-P109.		2
564	Alzheimer dementia with sparse amyloidâ€"AD mimic or variant?. Nature Reviews Neurology, 2015, 11, 674-675.	10.1	2
565	Synaptic and metabolic gene expression alterations in neurons that are recipients of proteopathic tau seeds. Acta Neuropathologica Communications, 2020, 8, 168.	5.2	2
566	LRP1 mediates tau endocytosis in a process that is modulated by apolipoprotein E. Alzheimer's and Dementia, 2020, 16, e045959.	0.8	2
567	Plasma biomarkers of neuroinflammation and vascular injury predict cognitive decline in patients with mild cognitive impairment. Alzheimer's and Dementia, 2020, 16, e046134.	0.8	2
568	O4-01-04: Entorhinal, parahippocampal, and inferior temporal F18-T807 SUVR correlates with CSF total tau and tau T181P in cognitively normal elderly. , 2015, 11, P267-P267.		1
569	616. Tailored Expression of a Transgene to Specific Cell Types in the Central Nervous System After Peripheral Injection of AAV9. Molecular Therapy, 2016, 24, S244.	8.2	1
570	The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. , 2011, 7, 263.		1
571	Active deep learning to detect cognitive concerns in electronic health records. Alzheimer's and Dementia, 2021, 17, e055362.	0.8	1
572	Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 1995, 54, 132.	1.7	0
573	Dementia with Lewy bodies. , 2002, , 267-282.		0
574	PL-05-01: A transgenic model of the earliest stage of Alzheimer's disease. , 2010, 6, S165-S165.		0
575	O1-05-01: APOE4 plays a role in Abeta-mediated synapse loss in Alzheimer's disease. , 2011, 7, S103-S104.		0
576	Plasma Î²-Amyloid Linked to Cognitive Decline. Archives of Neurology, 2011, 68, 799-801.	4.5	0

#	Article	IF	Citations
577	O2-01-01: Neurofibrillary tangles remain functionally integrated in cortical networks. , 2013, 9, P314-P314.		0
578	DT-01-02: TEMPORAL NEOCORTICAL TAU DEPOSITION MEASURED WITH PET IS ASSOCIATED WITH LONGITUDINAL DECLINE IN MEMORY PERFORMANCE AMONG CLINICALLY NORMAL ELDERLY. , 2014, 10, P280-P280.		0
579	P1-025: CONSEQUENCES OF APOE2 OVEREXPRESSION IN ASTROCYTES IN AN ALZHEIMER'S DISEASE MOUSE MODEL. , 2014, 10, P313-P313.		0
580	O4-03-05: NLRP1 INFLAMMASOME REGULATES CASPASE-1-MEDIATED CASPASE-6 ACTIVATION IN HUMAN NEURONS. , 2014, 10, P255-P255.		0
581	O4-09-04: UNRAVELING THE ROLE OF APOLIPOPROTEIN E IN AGE- AND ABETA-RELATED NEURONAL DYSFUNCTION. , 2014, 10, P269-P269.		0
582	P3-071: A unique high-molecular-weight tau species is involved in propagation and accumulates in the cerebrospinal fluid of Alzheimer's disease patients. , 2015, 11, P644-P644.		0
583	312. Highly-Efficient CNS Transduction With Vesicle-Associated AAV Vector. Molecular Therapy, 2015, 23, S126.	8.2	0
584	P1-027: Improved amyloid pathology contrasting with unexpected memory defects following astrocytic ApoE-e2 overexpression in hippocampus of Alzheimer's mice. , 2015, 11, P347-P347.		0
585	O2-06-01: Lack of endogenous tau permits tau spreading and protects against tau toxicity in transgenic mice. , 2015, 11, P186-P186.		0
586	S4-02-02: Modeling braak-like progression of tangles in the medial temporal lobe. , 2015, 11, P258-P258.		0
587	ECâ€03â€03: Tau Spreading and Toxicity. Alzheimer's and Dementia, 2016, 12, P269.	0.8	0
588	Metaâ€analysis of mouse transcriptomic studies supports a contextâ€dependent astrocyte reaction in acute CNS injury versus neurodegeneration. Alzheimer's and Dementia, 2020, 16, e040699.	0.8	0
589	Brain transcriptomes and plasma proteins reveal upregulation of a proinflammatory signature in APOE e4 carriers. Alzheimer's and Dementia, 2020, 16, e041316.	0.8	0
590	In Situ Studies of Fibrillar Polymorphs in Alzheimer's Disease. Biophysical Journal, 2021, 120, 351a-352a.	0.5	0
591	Impact of Sterilization Methods on the Seeding Ability of Human Tau Proteopathic Seeds. Journal of Neuropathology and Experimental Neurology, 2021, 80, 912-921.	1.7	0
592	In reply to Zou et al. â€œNew amyloid plaques or a game of hide-and-seek?â€• International Journal of Biological Sciences, 2008, 4, 245-245.	6.4	0
593	Tau propagation is dependent on the genetic background in multiple mouse strains. Alzheimer's and Dementia, 2020, 16, e043059.	0.8	0
594	In situ structural biology of pathological protein deposits in Alzheimer's disease. Biophysical Journal, 2022, 121, 153a.	0.5	0

#	Article	IF	Citations
595	Characterization of glial responses in Alzheimerâ€™s disease with cyclic multiplex fluorescent immunohistochemistry and machine learning. Alzheimer's and Dementia, 2021, 17, e050902.	0.8	0
596	Rateâ€limiting processes of tau aggregate accumulation in Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, .	0.8	0
597	Optimization of biosensor cell lines for the detection of tau seeding competency in human CSF. Alzheimer's and Dementia, 2021, 17, .	0.8	0
598	Heterogeneity of tau deposition and microvascular involvement in MCI and AD.. Alzheimer's and Dementia, 2021, 17 Suppl 3, e054282.	0.8	0